CN110840812A - 胎体来源的外泌体在皮肤调节产品中的用途 - Google Patents
胎体来源的外泌体在皮肤调节产品中的用途 Download PDFInfo
- Publication number
- CN110840812A CN110840812A CN201911179142.8A CN201911179142A CN110840812A CN 110840812 A CN110840812 A CN 110840812A CN 201911179142 A CN201911179142 A CN 201911179142A CN 110840812 A CN110840812 A CN 110840812A
- Authority
- CN
- China
- Prior art keywords
- product
- skin
- exosomes
- carcass
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001808 exosome Anatomy 0.000 title claims abstract description 269
- 230000003750 conditioning effect Effects 0.000 title claims abstract description 13
- 210000003491 skin Anatomy 0.000 claims abstract description 67
- 230000014509 gene expression Effects 0.000 claims abstract description 62
- 210000004027 cell Anatomy 0.000 claims abstract description 54
- 210000002510 keratinocyte Anatomy 0.000 claims abstract description 43
- 210000003780 hair follicle Anatomy 0.000 claims abstract description 35
- 239000000428 dust Substances 0.000 claims abstract description 34
- 230000003712 anti-aging effect Effects 0.000 claims abstract description 32
- 230000001965 increasing effect Effects 0.000 claims abstract description 28
- 239000012528 membrane Substances 0.000 claims abstract description 24
- 210000002950 fibroblast Anatomy 0.000 claims abstract description 20
- 108010035532 Collagen Proteins 0.000 claims abstract description 17
- 102000008186 Collagen Human genes 0.000 claims abstract description 17
- 229920001436 collagen Polymers 0.000 claims abstract description 17
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 16
- 206010000496 acne Diseases 0.000 claims abstract description 16
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 15
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 13
- 239000011159 matrix material Substances 0.000 claims abstract description 13
- 230000001737 promoting effect Effects 0.000 claims abstract description 12
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 12
- 201000004384 Alopecia Diseases 0.000 claims abstract description 11
- 230000002438 mitochondrial effect Effects 0.000 claims abstract description 11
- 210000000130 stem cell Anatomy 0.000 claims abstract description 11
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract description 10
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 10
- 230000003833 cell viability Effects 0.000 claims abstract description 9
- 230000002407 ATP formation Effects 0.000 claims abstract description 8
- 230000006378 damage Effects 0.000 claims abstract description 8
- 102000035195 Peptidases Human genes 0.000 claims abstract description 7
- 108091005804 Peptidases Proteins 0.000 claims abstract description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000001301 oxygen Substances 0.000 claims abstract description 7
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 7
- 230000004936 stimulating effect Effects 0.000 claims abstract description 7
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims abstract description 6
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims abstract description 6
- 239000004365 Protease Substances 0.000 claims abstract description 6
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 6
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims abstract description 6
- 230000002503 metabolic effect Effects 0.000 claims abstract description 5
- 230000005808 skin problem Effects 0.000 claims abstract description 5
- 102000013370 fibrillin Human genes 0.000 claims abstract description 4
- 108060002895 fibrillin Proteins 0.000 claims abstract description 4
- 210000002966 serum Anatomy 0.000 claims description 99
- 239000000047 product Substances 0.000 claims description 80
- 230000001605 fetal effect Effects 0.000 claims description 79
- 239000006228 supernatant Substances 0.000 claims description 62
- 239000000203 mixture Substances 0.000 claims description 60
- 239000002244 precipitate Substances 0.000 claims description 30
- 239000008055 phosphate buffer solution Substances 0.000 claims description 24
- 238000001914 filtration Methods 0.000 claims description 20
- 230000002708 enhancing effect Effects 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 239000012530 fluid Substances 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 14
- 238000012258 culturing Methods 0.000 claims description 12
- 239000003963 antioxidant agent Substances 0.000 claims description 11
- 230000003078 antioxidant effect Effects 0.000 claims description 10
- 210000004185 liver Anatomy 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 8
- 230000001464 adherent effect Effects 0.000 claims description 8
- 210000000056 organ Anatomy 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 7
- 108010053835 Catalase Proteins 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 7
- 208000024963 hair loss Diseases 0.000 claims description 7
- 230000003676 hair loss Effects 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 230000037394 skin elasticity Effects 0.000 claims description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 6
- 102100033039 Glutathione peroxidase 1 Human genes 0.000 claims description 6
- 101001014936 Homo sapiens Glutathione peroxidase 1 Proteins 0.000 claims description 6
- 101001045846 Homo sapiens Histone-lysine N-methyltransferase 2A Proteins 0.000 claims description 6
- 101000973778 Homo sapiens NAD(P)H dehydrogenase [quinone] 1 Proteins 0.000 claims description 6
- 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 claims description 6
- 102100036407 Thioredoxin Human genes 0.000 claims description 6
- 235000013361 beverage Nutrition 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 6
- 230000032683 aging Effects 0.000 claims description 5
- 239000010868 animal carcass Substances 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 239000012894 fetal calf serum Substances 0.000 claims description 5
- 229920006395 saturated elastomer Polymers 0.000 claims description 5
- 210000001835 viscera Anatomy 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 102000029816 Collagenase Human genes 0.000 claims description 4
- 108060005980 Collagenase Proteins 0.000 claims description 4
- 108010019160 Pancreatin Proteins 0.000 claims description 4
- 229960002424 collagenase Drugs 0.000 claims description 4
- 239000012228 culture supernatant Substances 0.000 claims description 4
- 229940088592 immunologic factor Drugs 0.000 claims description 4
- 229940055695 pancreatin Drugs 0.000 claims description 4
- 239000004017 serum-free culture medium Substances 0.000 claims description 4
- 238000005728 strengthening Methods 0.000 claims description 4
- 210000001185 bone marrow Anatomy 0.000 claims description 3
- 230000004663 cell proliferation Effects 0.000 claims description 3
- 238000005520 cutting process Methods 0.000 claims description 3
- 235000013365 dairy product Nutrition 0.000 claims description 3
- 239000008363 phosphate buffer Substances 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 2
- 235000011868 grain product Nutrition 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims 2
- 239000000917 skin toxin Substances 0.000 claims 2
- 102100035882 Catalase Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 210000003850 cellular structure Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 28
- 230000002265 prevention Effects 0.000 abstract description 6
- 230000035755 proliferation Effects 0.000 abstract description 5
- 210000004209 hair Anatomy 0.000 abstract description 4
- 231100000360 alopecia Toxicity 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 abstract description 3
- 239000003053 toxin Substances 0.000 abstract description 3
- 231100000765 toxin Toxicity 0.000 abstract description 3
- 238000013459 approach Methods 0.000 abstract description 2
- 230000003656 anti-hair-loss Effects 0.000 abstract 1
- 108700012359 toxins Proteins 0.000 abstract 1
- 241001494479 Pecora Species 0.000 description 83
- 239000002609 medium Substances 0.000 description 75
- 108090000623 proteins and genes Proteins 0.000 description 26
- 241000282836 Camelus dromedarius Species 0.000 description 24
- 239000000284 extract Substances 0.000 description 19
- 239000002537 cosmetic Substances 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 16
- 241000186427 Cutibacterium acnes Species 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- 239000002245 particle Substances 0.000 description 14
- 229940055019 propionibacterium acne Drugs 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 13
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 13
- 102000004890 Interleukin-8 Human genes 0.000 description 11
- 108090001007 Interleukin-8 Proteins 0.000 description 11
- 244000025272 Persea americana Species 0.000 description 11
- 235000008673 Persea americana Nutrition 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- -1 patches Substances 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- 210000002826 placenta Anatomy 0.000 description 8
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 7
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 7
- 102100028717 Cytosolic 5'-nucleotidase 3A Human genes 0.000 description 7
- 102000004125 Interleukin-1alpha Human genes 0.000 description 7
- 108010082786 Interleukin-1alpha Proteins 0.000 description 7
- 241000219745 Lupinus Species 0.000 description 7
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 7
- 102000016938 Catalase Human genes 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 6
- 102000003777 Interleukin-1 beta Human genes 0.000 description 6
- 108090000193 Interleukin-1 beta Proteins 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 238000013456 study Methods 0.000 description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 235000010469 Glycine max Nutrition 0.000 description 5
- 244000068988 Glycine max Species 0.000 description 5
- 101001124867 Homo sapiens Peroxiredoxin-1 Proteins 0.000 description 5
- 102100029139 Peroxiredoxin-1 Human genes 0.000 description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 239000010949 copper Substances 0.000 description 5
- 229910052802 copper Inorganic materials 0.000 description 5
- 229940108928 copper Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 5
- 239000002417 nutraceutical Substances 0.000 description 5
- 235000021436 nutraceutical agent Nutrition 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 230000009759 skin aging Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 235000018553 tannin Nutrition 0.000 description 5
- 239000001648 tannin Substances 0.000 description 5
- 229920001864 tannin Polymers 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 4
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 4
- 238000009010 Bradford assay Methods 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 102100038055 Glutathione S-transferase theta-1 Human genes 0.000 description 4
- 101001032462 Homo sapiens Glutathione S-transferase theta-1 Proteins 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 4
- 235000000421 Lepidium meyenii Nutrition 0.000 description 4
- 240000000759 Lepidium meyenii Species 0.000 description 4
- 206010051246 Photodermatosis Diseases 0.000 description 4
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 235000014121 butter Nutrition 0.000 description 4
- 230000005779 cell damage Effects 0.000 description 4
- 229940106189 ceramide Drugs 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 238000003633 gene expression assay Methods 0.000 description 4
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 235000012902 lepidium meyenii Nutrition 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000002731 protein assay Methods 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 210000002374 sebum Anatomy 0.000 description 4
- 229910052710 silicon Inorganic materials 0.000 description 4
- 239000010703 silicon Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 230000000475 sunscreen effect Effects 0.000 description 4
- 239000000516 sunscreening agent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 230000037303 wrinkles Effects 0.000 description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 3
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical class C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 3
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 235000003880 Calendula Nutrition 0.000 description 3
- 240000001432 Calendula officinalis Species 0.000 description 3
- 241000282832 Camelidae Species 0.000 description 3
- 241000282994 Cervidae Species 0.000 description 3
- 240000006162 Chenopodium quinoa Species 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- 102000012432 Collagen Type V Human genes 0.000 description 3
- 108010022514 Collagen Type V Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102100031509 Fibrillin-1 Human genes 0.000 description 3
- 108010030229 Fibrillin-1 Proteins 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 3
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 235000019484 Rapeseed oil Nutrition 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 229930003537 Vitamin B3 Natural products 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 208000037887 cell injury Diseases 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 230000021995 interleukin-8 production Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000001630 malic acid Substances 0.000 description 3
- 235000011090 malic acid Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 230000008845 photoaging Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 235000020944 retinol Nutrition 0.000 description 3
- 239000011607 retinol Substances 0.000 description 3
- 229960003471 retinol Drugs 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 235000019160 vitamin B3 Nutrition 0.000 description 3
- 239000011708 vitamin B3 Substances 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 235000016804 zinc Nutrition 0.000 description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 2
- 239000001500 (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 2
- 244000235603 Acacia catechu Species 0.000 description 2
- 239000001904 Arabinogalactan Substances 0.000 description 2
- 229920000189 Arabinogalactan Polymers 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- 102100025222 CD63 antigen Human genes 0.000 description 2
- 102100027221 CD81 antigen Human genes 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 2
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 2
- 101000836492 Dictyostelium discoideum ALG-2 interacting protein X Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 description 2
- CJPNHKPXZYYCME-UHFFFAOYSA-N Genistin Natural products OCC1OC(Oc2ccc(O)c3OC(=CC(=O)c23)c4ccc(O)cc4)C(O)C(O)C1O CJPNHKPXZYYCME-UHFFFAOYSA-N 0.000 description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 description 2
- 244000194101 Ginkgo biloba Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 2
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 2
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 2
- 101001134621 Homo sapiens Programmed cell death 6-interacting protein Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 235000010649 Lupinus albus Nutrition 0.000 description 2
- 240000000894 Lupinus albus Species 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- YCUNGEJJOMKCGZ-UHFFFAOYSA-N Pallidiflorin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC(O)=C2C1=O YCUNGEJJOMKCGZ-UHFFFAOYSA-N 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 240000008440 Passiflora incarnata Species 0.000 description 2
- 235000011922 Passiflora incarnata Nutrition 0.000 description 2
- 102100033344 Programmed cell death 6-interacting protein Human genes 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241001416177 Vicugna pacos Species 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 2
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 235000019312 arabinogalactan Nutrition 0.000 description 2
- 235000021302 avocado oil Nutrition 0.000 description 2
- 239000008163 avocado oil Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 2
- 229960002747 betacarotene Drugs 0.000 description 2
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- 229940110767 coenzyme Q10 Drugs 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000007240 daidzein Nutrition 0.000 description 2
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 235000007882 dietary composition Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 229960003720 enoxolone Drugs 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 235000021189 garnishes Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000006539 genistein Nutrition 0.000 description 2
- 229940045109 genistein Drugs 0.000 description 2
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 2
- 229910000271 hectorite Inorganic materials 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 150000001261 hydroxy acids Chemical class 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 150000002515 isoflavone derivatives Chemical class 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- 239000003410 keratolytic agent Substances 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- MQYXUWHLBZFQQO-QGTGJCAVSA-N lupeol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C MQYXUWHLBZFQQO-QGTGJCAVSA-N 0.000 description 2
- PKGKOZOYXQMJNG-UHFFFAOYSA-N lupeol Natural products CC(=C)C1CC2C(C)(CCC3C4(C)CCC5C(C)(C)C(O)CCC5(C)C4CCC23C)C1 PKGKOZOYXQMJNG-UHFFFAOYSA-N 0.000 description 2
- 235000012680 lutein Nutrition 0.000 description 2
- 239000001656 lutein Substances 0.000 description 2
- 229960005375 lutein Drugs 0.000 description 2
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 2
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 2
- 235000012661 lycopene Nutrition 0.000 description 2
- 239000001751 lycopene Substances 0.000 description 2
- 229960004999 lycopene Drugs 0.000 description 2
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 2
- 229940081510 piroctone olamine Drugs 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 235000011649 selenium Nutrition 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 229940091258 selenium supplement Drugs 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 208000009056 telangiectasis Diseases 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- OWVLYQRCCIEOPF-QHTZZOMLSA-L zinc;(2s)-5-oxopyrrolidine-2-carboxylate Chemical compound [Zn+2].[O-]C(=O)[C@@H]1CCC(=O)N1.[O-]C(=O)[C@@H]1CCC(=O)N1 OWVLYQRCCIEOPF-QHTZZOMLSA-L 0.000 description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
- HEOCBCNFKCOKBX-RELGSGGGSA-N (1s,2e,4r)-4,7,7-trimethyl-2-[(4-methylphenyl)methylidene]bicyclo[2.2.1]heptan-3-one Chemical compound C1=CC(C)=CC=C1\C=C/1C(=O)[C@]2(C)CC[C@H]\1C2(C)C HEOCBCNFKCOKBX-RELGSGGGSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- TYYHDKOVFSVWON-UHFFFAOYSA-N 2-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)(CCCC)C(=O)C1=CC=CC=C1 TYYHDKOVFSVWON-UHFFFAOYSA-N 0.000 description 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- LKLYETYHDMXRAF-UHFFFAOYSA-N 2-octanoyloxybenzoic acid Chemical compound CCCCCCCC(=O)OC1=CC=CC=C1C(O)=O LKLYETYHDMXRAF-UHFFFAOYSA-N 0.000 description 1
- VSDNNWKISVRDNT-UHFFFAOYSA-N 2-octoxybenzoic acid Chemical compound CCCCCCCCOC1=CC=CC=C1C(O)=O VSDNNWKISVRDNT-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 235000006020 Acacia catechu Nutrition 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241001530056 Athelia rolfsii Species 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 235000000832 Ayote Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 241000093727 Berzelia alopecuroides Species 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 235000003363 Cornus mas Nutrition 0.000 description 1
- 240000006766 Cornus mas Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241000219122 Cucurbita Species 0.000 description 1
- 240000004244 Cucurbita moschata Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000239366 Euphausiacea Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 241000208681 Hamamelis virginiana Species 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 244000061944 Helianthus giganteus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000604197 Homo sapiens Neuronatin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 241000555688 Malassezia furfur Species 0.000 description 1
- 108010091175 Matriptase Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- SAVLIIGUQOSOEP-UHFFFAOYSA-N N-octanoylglycine Chemical compound CCCCCCCC(=O)NCC(O)=O SAVLIIGUQOSOEP-UHFFFAOYSA-N 0.000 description 1
- 102100038816 Neuronatin Human genes 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 229920002292 Nylon 6 Polymers 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- WYWZRNAHINYAEF-UHFFFAOYSA-N Padimate O Chemical compound CCCCC(CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-UHFFFAOYSA-N 0.000 description 1
- 235000011925 Passiflora alata Nutrition 0.000 description 1
- 235000000370 Passiflora edulis Nutrition 0.000 description 1
- 235000013750 Passiflora mixta Nutrition 0.000 description 1
- 235000013731 Passiflora van volxemii Nutrition 0.000 description 1
- 206010049752 Peau d'orange Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 244000264479 Persea americana guatemalensis Species 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 238000001190 Q-PCR Methods 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 235000011552 Rhamnus crocea Nutrition 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 240000006661 Serenoa repens Species 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- XDLGATIAMPGERU-UHFFFAOYSA-N [2-[[4-[[7,7-dimethyl-3-oxo-4-(sulfomethyl)-2-bicyclo[2.2.1]heptanyl]methyl]phenyl]methyl]-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid Chemical compound CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)C2CC(C=C1)=CC=C1CC1C(=O)C2(CS(O)(=O)=O)CCC1C2(C)C XDLGATIAMPGERU-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000001560 acacia catechu Substances 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960002916 adapalene Drugs 0.000 description 1
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000003367 anti-collagen effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 description 1
- 229940011658 asiatic acid Drugs 0.000 description 1
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 229960005193 avobenzone Drugs 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- XVAMCHGMPYWHNL-UHFFFAOYSA-N bemotrizinol Chemical compound OC1=CC(OCC(CC)CCCC)=CC=C1C1=NC(C=2C=CC(OC)=CC=2)=NC(C=2C(=CC(OCC(CC)CCCC)=CC=2)O)=N1 XVAMCHGMPYWHNL-UHFFFAOYSA-N 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 229940024874 benzophenone Drugs 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- 150000001277 beta hydroxy acids Chemical class 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- FQUNFJULCYSSOP-UHFFFAOYSA-N bisoctrizole Chemical compound N1=C2C=CC=CC2=NN1C1=CC(C(C)(C)CC(C)(C)C)=CC(CC=2C(=C(C=C(C=2)C(C)(C)CC(C)(C)C)N2N=C3C=CC=CC3=N2)O)=C1O FQUNFJULCYSSOP-UHFFFAOYSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 229940110716 cicatrizants Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014541 cooking fats Nutrition 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960004697 enzacamene Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- QOLIPNRNLBQTAU-UHFFFAOYSA-N flavan Chemical group C1CC2=CC=CC=C2OC1C1=CC=CC=C1 QOLIPNRNLBQTAU-UHFFFAOYSA-N 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 229920001461 hydrolysable tannin Polymers 0.000 description 1
- 229920013818 hydroxypropyl guar gum Polymers 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical class CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 239000002973 irritant agent Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 229940106134 krill oil Drugs 0.000 description 1
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- PRAUVHZJPXOEIF-AOLYGAPISA-N madecassic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2[C@H](O)C[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C PRAUVHZJPXOEIF-AOLYGAPISA-N 0.000 description 1
- 229940011656 madecassic acid Drugs 0.000 description 1
- BUWCHLVSSFQLPN-UHFFFAOYSA-N madecassic acid Natural products CC1CCC2(CCC3(C)C(=CCC4C5(C)CC(O)C(O)C(C)(C5CCC34C)C(=O)O)C2C1C)C(=O)OC6OC(COC7OC(CO)C(OC8OC(C)C(O)C(O)C8O)C(O)C7O)C(O)C(O)C6O BUWCHLVSSFQLPN-UHFFFAOYSA-N 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 235000019520 non-alcoholic beverage Nutrition 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical class CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 235000008519 pasta sauces Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229940067631 phospholipid Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000011197 physicochemical method Methods 0.000 description 1
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 description 1
- 229940033329 phytosphingosine Drugs 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 235000015136 pumpkin Nutrition 0.000 description 1
- 239000008171 pumpkin seed oil Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 235000020945 retinal Nutrition 0.000 description 1
- 239000011604 retinal Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229940084038 salix alba bark extract Drugs 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910000338 selenium disulfide Inorganic materials 0.000 description 1
- JNMWHTHYDQTDQZ-UHFFFAOYSA-N selenium sulfide Chemical compound S=[Se]=S JNMWHTHYDQTDQZ-UHFFFAOYSA-N 0.000 description 1
- 229960005265 selenium sulfide Drugs 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940058349 sodium levulinate Drugs 0.000 description 1
- RDKYCKDVIYTSAJ-UHFFFAOYSA-M sodium;4-oxopentanoate Chemical compound [Na+].CC(=O)CCC([O-])=O RDKYCKDVIYTSAJ-UHFFFAOYSA-M 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000014348 vinaigrettes Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229940043810 zinc pyrithione Drugs 0.000 description 1
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/982—Reproductive organs; Embryos, Eggs
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D13/00—Finished or partly finished bakery products
- A21D13/06—Products with modified nutritive value, e.g. with modified starch content
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/34—Animal material
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C15/00—Butter; Butter preparations; Making thereof
- A23C15/12—Butter preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C19/00—Cheese; Cheese preparations; Making thereof
- A23C19/06—Treating cheese curd after whey separation; Products obtained thereby
- A23C19/09—Other cheese preparations; Mixtures of cheese with other foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
- A23G4/12—Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
- A23G9/32—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
- A23G9/36—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Reproductive Health (AREA)
- Developmental Biology & Embryology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Abstract
本发明提供了胎体来源的外泌体在皮肤调节产品中的用途,通过实验证实,该外泌体通过促进细胞胶原蛋白表达、增加细胞肌原纤蛋白合成、维持干细胞干性以及刺激干细胞增殖实现抗衰老功能;通过抑制角质形成细胞中炎症介质或基质蛋白酶的基因表达的产品、以及抑制角质形成细胞中VEGF合成和释放实现对抗痤疮的药学功能;通过促进毛囊乳头成纤维细胞中ATP合成或增强线粒体代谢活性的产品、增加微毛囊的细胞存活力或减轻微毛囊膜损伤,实现增强毛囊、抗脱发的皮肤病学用途;通过清除和排除毒素、增加皮肤抗微生物肽hBD3表达、抑制活性氧产生预防由亚洲沙尘引起的皮肤问题,为抗衰老皮肤护理、痤疮对抗、防脱发、预防沙尘影响等皮肤护理提供了一种新的途径。
Description
技术领域
本发明属于生物皮肤调节产品技术领域,具体涉及一种胎体来源的外泌体在皮肤调节产品中的用途以及包含该外泌体的皮肤调节产品。
背景技术
在化妆品领域,“羊胎素”的概念和生物医学效应是具有争议性的。较为早期的记录是1931年,瑞士保罗尼翰医生(Dr.Paul Niehans)首次将从小羊胎体中来源的甲状旁腺鲜活细胞注射应用,这就是胎羊素细胞活化疗法的最初起源,它的发现对人类在抗衰老领域的医学发展有着里程碑式的意义,因此Paul Niehans被世人誉称为“活细胞之父”、“胎羊素细胞活化治疗的创始人”,罗马教皇为了表示对Dr.Paul Niehans的敬意,授封PaulNiehans为梵蒂冈科学院院士。
记载描述性的文献并未对羊胎素的实际成分进行描述,目前市面上的羊胎素产品,多以物理化学手段打碎裂解羊胎,再进一步获取其中的蛋白质等分子。一方面,其生物学效应有待进一步观察,一般认为比较有争议。另一方面,和保罗尼翰所述的羊胎疗法已经区别很大。因此,羊胎素的活性成分未明确,一直是困扰领域内的科学问题。
值得关注的是,现代生命科学证实:活细胞能分泌大量的外泌体(exosome),外泌体是胞内体逆出芽形成多囊泡胞内体,多囊泡胞内体与细胞膜融合,向细胞外释放形成外泌体。几乎所有的细胞都可以分泌外泌体。这些外泌体的特点是:直径在30-150nm之间;密度在1.13-1.19g/mL之间;表达特异性的蛋白,携带了亲本细胞的重要信号分子,包括蛋白质、脂质和RNA等;保持着与亲代细胞相似的生活学活性。特别的是,一旦细胞死亡,外泌体的分泌量则立刻降低,说明外泌体是活细胞分泌的一种活性效应物。
哺乳动物的脐带、胎盘等是外泌体的重要来源,从哺乳动物的脐带或胎盘中提取外泌体并用于皮肤调理的研究不少,但未见以动物胎体作为该类外泌体来源的研究。在少数以动物胎体作为原材料进行物质提取的研究中,其提取物多集中在小分子量的水溶性分子,如专利文献CN 103462864B公开了从动物胎体内脏如分离分子量小于4000D的水溶性分子用于化妆品和食品生产的用途。然而公开的是分子量小于4000D的水溶性分子,并不是外泌体;专利文献CN 103462865 B公开了从从动物胎体皮肤及肌肉中提取分子量为5000D以下分子量的水提物和用途,然而公开的是分子量小于5000D的水溶性分子,并不是外泌体。
因而,没有现有技术公开或提示胎体内脏、体液提取的外泌体用于化妆品和食品用途。
发明内容
本发明是为解决上述技术问题进行的,目的在于提供胎体来源的外泌体在皮肤调节产品中的用途、该外泌体的制备方法以及以该外泌体作为活性成分的皮肤调节产品。
本发明的第一方面在于提供了胎体来源的外泌体在皮肤调节产品中的用途。该外泌体是提取自非人胎生动物胎体、新生体内脏器或生理性流体内的外泌体。
所述的胎体指非人胎生动物母体内的幼体和新出生动物,不包括胎儿附属物。优选羊、牛、鹿和骆驼,即胎羊、胎牛、胎鹿和胎骆驼;动物幼体优选是至少2月龄的胎羊、至少4月龄的胎牛、至少3月龄的胎鹿、至少6月龄的胎骆驼;新生体指自然分娩后24小时内的新生动物。
所述脏器包括肺、乳房、胃、胰、前列腺、膀胱、骨、卵巢及附件、子宫、皮肤、肾、窦、结肠、直肠、食道、血液、大脑和其覆盖物、脊髓和其覆盖物、肌肉、结缔组织、肾上腺、副甲状腺、甲状腺、睾丸、垂体、生殖器、肝脏、胆囊、眼、耳、鼻、喉、扁桃腺、口、淋巴结和淋巴系统及其它器官;优选是肝脏,骨髓。
所述生理性流体包括以下的流体:鼻咽、口腔、食道、胃、胰腺、肝、胸膜、心包、腹膜、肠、前列腺、精液、阴道分泌物、眼泪、唾液、粘液、胆汁、血液、淋巴、血浆、血清、滑液、脑脊液、宫腔及附件、尿,以及间隙、细胞内和细胞外的流体;优选是血液、血浆和血清。
发明人意外发现上述外泌体具有促进细胞增殖、提高细胞存活能力、促进细胞ATP合成、提高线粒体活性、减轻炎症反应和细胞衰老以及增加一些局部靶标的表达,该提取物在增加细胞活力、抗衰老方面是有效的。即在应用方面,发明人发现外泌体具有美容化妆和皮肤病学用途,美容化妆和皮肤病学用途包括抗衰老、增强皮肤弹性、对抗痤疮、增强毛囊、抗脱发等。
因此,本发明所述的皮肤调节产品包括直接涂抹式护肤产品、口服式皮肤调理产品或皮肤病学用途产品。
优选的,直接涂抹式护肤产品为抗衰老或增强皮肤弹性的护肤产品;口服式皮肤调理产品包括含有该外泌体的乳制品、基于脂肪制品、饮料制品或谷物制品;皮肤病学用途产品为对抗痤疮或增强毛囊、抗脱发的皮肤病学用途产品。
更优选的,抗衰老或增强皮肤弹性的护肤产品为促进细胞胶原蛋白表达、增加细胞肌原纤蛋白合成、维持干细胞干性以及刺激干细胞增殖的护肤产品中的一种或多种组合;对抗痤疮的皮肤病学用途产品为抑制角质形成细胞中炎症介质或基质蛋白酶的基因表达的产品、以及抑制角质形成细胞中VEGF合成和释放产品中的一种或两种组合;增强毛囊、抗脱发的皮肤病学用途产品为促进毛囊乳头成纤维细胞中ATP合成或增强线粒体代谢活性的产品、增加微毛囊的细胞存活力或减轻微毛囊膜损伤产品中的任意一种或两种。
根据实施例,本发明胎体来源的外泌体意图通过刺激增殖、维持干细胞活性的特异性作用抗衰老、促愈合。因而,下文提出的实例显示外泌体针对人间充质干细胞细胞具有以下几种作用:增加ALDH阳性细胞比率、Ki67比率的表达。
此外,还意图通过针对痤疮丙酸杆菌的特异性作用抑制炎症。外泌体特异地锁定在病变发展和加重中发挥核心作用的痤疮炎性过程。因而,下文提出的实例显示外泌体针对角质形成细胞具有以下几种作用:
抗炎作用:抑制炎症早期介质(IL-1α,IL-1β)和晚期介质(IL-8);对角质形成细胞诱导MMP(MMP-2和MMP-9)的抑制作用;对VEGF释放的抑制作用。
外泌体也对痤疮丙酸杆菌具有以下作用:抑制痤疮丙酸杆菌诱导IL-8;抑制痤疮丙酸杆菌诱导MMP-9。
因此,将该胎体来源的外泌体局部或口服施用用于维持和/或增加V型胶原蛋白和/或肌原纤蛋白-1表达和/或用于增加毛囊成纤维细胞增殖和/或用于增加细胞存活力和/或ATP合成和/或线粒体活性和/或减轻细胞损伤和/或减轻细胞衰老,用于增强毛囊,进而减少皮肤附属器损失,如脱发。
在本发明的一些具体的实施方案中,本发明所述胎体来源的外泌体局部或口服施用用于:通过增加抗氧化酶NQO1(Entrez Gene:1728)和GSTT1(Entrez Gene:2952)的表达实现清除和排除毒素;通过增加天然免疫因子的皮肤抗微生物肽hBD3(Entrez Gene:55894)的表达实现对皮肤的保护;以及通过增加抗氧化蛋白GPX1(Entrez Gene:2876)、过氧化氢酶(catalase,Entrez Gene:847)、TRX1(Entrez Gene:7295)和PRDX1(Entrez Gene:5052)的表达来实现抑制活性氧的产生。因此,组合物可以用作预防由亚洲沙尘(PM2.5)引起的皮肤问题、保护皮肤以及预防和治疗皮肤老化的药物组合物或美容组合物。
本发明的第二方面在于,提供了胎体来源外泌体的制备方法,由包括如下步骤的方法制备得到:
(1)脏器细胞分离和培养液收集
取无菌脏器,经磷酸盐缓冲液(PBS)反复冲洗后,剪成直径约1-2mm的组织块;经2型胶原酶和胰酶消化依次后,将上清液离心,取细胞沉淀放入培养瓶,使用含10%胎牛血清DMEM/F12培养基,5%CO2、37℃饱和湿度培养;去除非贴壁细胞,在贴壁细胞80%融合后更换无血清培养基培养48h;收集培养上清液;0.45μm滤膜过滤得到富含外泌体的培养液。
(2)生理性流体内预处理
对于血液等生理性流体,首先利用离心、过滤等方法去除生理性流体内的细胞成分。0.45μm滤膜过滤得到富含外泌体的流体。
(2)外泌体分离纯化包括:将培养液或流体在4℃,1000g离心10min,收集上清;收集的上清液4℃,2000g离心20min,收集上清;收集的上清液4℃,10000g离心30min,收集上清;收集的上清液,110000g离心90min,弃上清,使用磷酸盐缓冲液重悬沉淀;再次110000g离心90min,弃上清,少量磷酸盐缓冲液重悬沉淀,0.45μm滤膜过滤,得到外泌体。
根据上述方法制备得到的外泌体,具有如下特征:直径约为30-150nm,具有脂质膜,内包裹蛋白质和mRNA、microRNA等遗传物质。经蛋白分析含有CD63、CD81、Alix等蛋白分子。
本发明的第三方面,提供了含有外泌体为活性成分的组合物。该组合物包含至少一种可药用的赋形剂,特别是美容和皮肤病学可接受的赋形剂。如该赋形剂可以是适于体外局部施加的赋形剂,也可以是能够供人体应用的赋形剂。
根据第一变例,多种制剂适于局部施加,并且包括乳膏剂、凝胶剂、乳化剂、乳液剂、香膏剂、洗剂、油剂、水溶液剂或氢化-醇或乙醇酸溶液剂、粉剂、贴剂、喷雾剂或用于外部施加的任何其他产品。在下文实例中提出此类制剂。
根据第二变例,多种制剂适于口服施用,其中可以在膳食补充剂或膳食组合物中包含所述外泌体。
在本发明背景下,可以以硬质或软质明胶或植物胶囊剂的形式提供膳食补充剂。所述膳食补充剂因而可以含有以重量计1%至100%的外泌体。
在不限制的情况下,也可以在膳食组合物如食物、饮料和营养药中并入本发明的外泌体,所述膳食组合物包括以下制品:
1)乳制品如乳酪、黄油、乳和其他乳状饮料,含有乳产品、冰淇淋和酸乳的混合物和糊状食品;
2)基于脂肪的制品如人造黄油、糊状食品、蛋黄酱、烹调用脂肪、油炸用油和维纳格雷酸辣沙司(vinaigrette);
3)由谷物组成的基于谷物的制品,如面包和面食制品,无论这些食品是否经过烹煮、焙烘或加工;
4)糖果如巧克力、糖食、口香糖、甜品、顶端配料(topping)、清凉果汁饮料(sorbet)、蛋糕糖衣(icing)和其他饰菜(garnishe);
5)酒精或无酒精饮料,包括苏打水和其他软饮料、果汁、膳食补充物、饮料形式的正餐代用品如在品牌名称BoostTM和EnsureTM下销售的那些正餐代用品,以及;
6)多种制品如蛋类、加工食品如汤、即用型面食制品调味汁、准备好的菜肴和相同类型的其他制品。
可以借助技术如混合、灌注、注射、掺混、吸附、揉捏和喷洒直接且无其他修饰下将外泌体并入食物中、营养药中、膳食产品,尤其高蛋白产品中或饮料中。
可以根据建立适于患者的药物疗法、尤其皮肤病学疗法时通常所考虑的标准例如,该患者的年龄或体重、该患者整体状态的严重性、对所述疗法的耐受性、明显的副作用和皮肤类型,确定本发明化合物和组合物的施用模式及、给药方案和最佳植物制剂形式。
本发明的第四方面还涉及美容治疗痤疮的方法,其特征在于将本发明的组合物施加至患病的皮肤区域或者患病的个体口服服用本发明的营养药组合物。
因此,本发明还可涉及将外泌体用于制备治疗或预防痤疮的化妆品、营养药或皮肤病学组合物的用途。
在美容或皮肤病学用途的背景下,将会优选地以适于局部施加的制剂形式配制所述组合物。
在用于食物中的背景下,针对营养或美容目的(美容食物),将会优选地以适于口服施用的制剂形式配制所述组合物。
本发明的美容化妆用护理方法包括将本发明的外泌体或包含其的组合物局部应用至选自如下的身体的全部或部分:腿,足,腋,手,大腿,腹部,颈线,颈,胳膊,躯干,背部,面部,皮肤附属器,优选毛发,和/或头皮,更有利地为头皮。
此外,本发明的组合物还可以包含本领域技术人员已知的至少一种药用佐剂,如增稠剂、防腐剂、香料、色料、化学或矿物遮光物、润湿剂、温泉水等。
本发明的组合物还可以包含选自皮脂调节剂、抗细菌剂、抗真菌剂、角质层分离剂、角质层调节剂、收敛剂、抗炎/抗刺激剂、抗氧化/自由基清除剂、结瘢剂、抗老化剂和/或润湿剂的至少一种抗衰老化合物。
术语“皮脂调节剂”例如指5-α-还原酶抑制剂,如活性物质锌及其葡萄糖酸盐、水杨酸盐和焦谷氨酸也具有皮脂抑制活性。也可以提到在12周应用后显著降低皮脂分泌速率的螺内酯,一种抗雄激素和醛固酮拮抗剂。其他的提取分子(例如来自西葫芦(Cucurbita pepo)的种子、南瓜种子油以及扇叶菜棕(palm cabbage))通过抑制5-α-还原酶转录和活性来限制皮脂产生。影响皮脂性质的其他脂源皮脂调节剂如亚油酸是也可以使用。
术语“抗细菌剂”和“抗真菌剂”指限制致病微生物如某些细菌如痤疮丙酸杆菌或某些真菌(糠秕马拉色菌(Malassezia furfur)生长或摧毁这些致病微生物的分子。最传统的是化妆品或营养药中通常使用的防腐剂,即具有抗细菌活性的分子(假防腐剂)如辛酸衍生物(辛酰甘氨酸、辛酸甘油酯等),如己二醇和乙酰丙酸钠、锌和铜衍生物(葡糖酸盐和PCA)、植物鞘氨醇及其衍生物、过氧苯甲酰、吡罗克酮乙醇胺、巯氧吡啶锌、二硫化硒、益康唑、酮康唑、或局部用抗生素如红霉素和克林霉素等。
术语“角质层调节剂”和“角质层分离剂”指调节或辅助表皮角质层死细胞消除的物质。常使用的角质层调节剂/角质层分离剂包括:最常使用的角质层调节剂/角质层分离剂包括:果实的α-羟酸(AHAS)(柠檬酸、羟乙酸、苹果酸、乳酸等)、AHA酯、AHAS与其他分子的组合如苹果酸和杏仁蛋白的组合羟乙酸或乳酸与精氨酸的组合或羟酸与脂质分子如(脂-羟酸)的组合、两性羟酸复合物(AHCare)、柳树皮(白柳树皮提取物)、壬二酸和其盐及酯、水杨酸及其衍生物如辛酰基水杨酸或与其他分子的组合如水杨酸和多糖(β-羟酸或BHA)的组合、他扎罗汀、阿达帕林、以及类视黄醇的分子如维甲酸、视黄醛、异维甲酸和视黄醇。
术语“收敛剂”指帮助收窄毛孔的物质,最常使用的是多酚、锌衍生物和北美金缕梅。
术语“抗炎性/抗刺激剂”指限制由细胞因子或花生四烯酸代谢介质引起的炎症反应并且具有顺滑和抗刺激性质的物质。最常规的是甘草次酸(甘草衍生物)及其盐和酯、α-没药醇、银杏(Ginkgo biloba)、金盏花(Calendula)、硫辛酸、β-胡萝卜素、维生素B3(烟酰胺尼古酰胺)、维生素E、维生素C、维生素B12、类黄酮(绿茶、槲皮素等)、番茄红素或叶黄素、鳄梨糖、鳄梨油精华素(avocado oleodistillate)、阿拉伯半乳聚糖、羽扇豆肽、羽扇豆总提取物、昆诺阿藜肽提取物、循环神经酰胺(噁唑啉衍生物)、抗糖化剂如肌肽、N-乙酰半胱氨酸、异黄酮例如染料木黄酮/染料木苷、黄豆苷原/黄豆苷、泉水或温泉水(雅漾(eau d′Avène)、理肤泉(eau de la Roche Posay)、圣泉薇(eau deSaintGervais)、依泉(eau d′Uriage)、珂玛德(eau de Gamarde)、枸杞(Lycium barbarum)提取物、植物氨基酸肽或复合物、局部用氨苯砜、或抗炎药。
术语“抗氧化剂”指减少或防止其他化学物质氧化的分子。可以组合使用的抗氧化/自由基清除剂优选地选自由以下物质组成的组:硫醇和酚、甘草衍生物如甘草次酸和其盐及酯、α-没药醇、银杏提取物、金盏花(Calendula)提取物、循环神经酰胺(噁唑啉衍生物)、鳄梨肽、微量元素如铜、锌和硒、硫辛酸、维生素B12、维生素B3(烟酰胺、尼古酰胺)、维生素C、维生素E、辅酶Q10、磷虾油(krill)、谷胱甘肽、丁羟甲苯(BHT)、丁羟茴醚(BHA)、番茄红素或叶黄素、β-胡萝卜素、多酚家族如单宁、酚酸、花青素、类黄酮,例如绿茶、红浆果、可可、葡萄、粉色西番莲(Passiflora incarnata)或柑橘(Citrus)的提取物,或异黄酮,例如染料木黄酮/染料木苷和黄豆苷元/黄豆苷。抗氧化剂类群还包括抗糖化剂如肌肽或某些肽、N-乙酰半胱氨酸以及抗氧化或自由基清除酶,如超氧化物歧化酶(SOD)、过氧化氢酶、谷胱甘肽过氧化物酶、硫氧还蛋白还原酶及其拮抗剂。
可以组合使用的生成瘢痕/修复屏障功能的物质优选地是维生素A、泛醇(维生素B5)、羽扇醇、玛卡肽提取物、昆诺阿藜肽提取物、阿拉伯半乳聚糖、氧化锌、镁、硅、羟基积雪草酸或积雪草酸、硫酸葡聚糖、辅酶Q10、葡糖胺及其衍生物、硫酸软骨素和总体糖胺聚糖(GAGs)、硫酸葡聚糖、神经酰胺、胆固醇、角鲨烷、磷脂、发酵或未发酵过的大豆肽、植物肽、海洋多糖、植物多糖或生物技术多糖,如藻类提取物或蕨类提取物、微量元素、富含单宁的植物的提取物如从没食子酸衍生的单宁,其称作没食性单宁或可水解单宁,最初在栎树瘿中找到,和从黄烷单元聚合产生的儿茶素单宁,其模型由儿茶(Acacia catechu)提供。可以使用的微量元素优选地选自由铜、镁、锰、铬、硒、硅、锌及其混合物组成。
最常使用的润湿剂/润肤剂是甘油或其衍生物、脲、吡咯烷酮羧酸及其衍生物、任何分子量的透明质酸、糖胺聚糖和海洋源、植物源或生物技术源的任何其他多糖,例如黄原胶、某些脂肪酸如月桂酸、肉豆蔻酸、单不饱和以及多不饱和ω-3、-6、-7和-9脂肪酸(亚油酸、棕榈油酸等)、向日葵油精华素(sunflower oleodistillate)、鳄梨肽和古朴阿苏果油(cupuacu butter)。
在本发明的一些优选的实施例中,本发明组合包括组合物,该组合物包含外泌体以及植物和动物不可皂化物,例如,鳄梨和大豆不可皂化物和不可皂化的植物油或动物油浓缩物,例如,向日葵油或棕榈油浓缩物,或含有不可皂化物的植物油,例如,大豆油和菜籽油,以及不可皂化物的衍生物如鳄梨呋喃、甾醇酯和维生素衍生物。
在本发明的一些优选的实施例中,本发明组合包括组合物,该组合物包含外泌体以及鳄梨糖(见申请WO2005/115421)。所述组合物特别适于治疗皮肤屏障修复和炎症。
在本发明的一些优选的实施例中,本发明组合包括组合物,该组合物包含外泌体和鳄梨肽(见国际申请WO2005/105123)。所述组合物特别适于治疗刺激和炎症。
在本发明的一些优选的实施例中,本发明组合包括组合物,该组合物包含外泌体以及鳄梨油(见国际申请WO2004/012496、WO2004/012752、WO2004/016106、WO2007/057439)。
在本发明的一些优选的实施例中,本发明组合包括组合物,该组合物包含外泌体以及(鳄梨呋喃,其可以通过国际申请WO01/21605中所述的方法获得)。所述组合物特别适于治疗炎症、促进瘢痕形成和适于其抗老化性质。
在本发明的一些优选的实施例中,本发明组合包括组合物,该组合物包含外泌体以及鳄梨和大豆不可皂化物。可以组合使用的鳄梨和大豆不可皂化物优选地分别是以大约1:3-2:3比例的鳄梨呋喃性不可皂化物和大豆不可皂化物的混合物。
在本发明的一些优选的实施例中,本发明组合包括组合物,该组合物包含外泌体以及羽扇醇(FR2822821,FR2857596)。所述组合物特别适于支持瘢痕形成。
在本发明的一些优选的实施例中,本发明组合包括组合物,该组合物包含外泌体以及羽扇豆肽,如根据申请WO2005/102259中所述的方法获得的羽扇豆肽。所述组合物特别适于治疗炎症,并且因其抗老化性质而使用。
在本发明的一些优选的实施例中,本发明组合包括组合物,该组合物包含外泌体以及总羽扇豆提取物(见国际申请WO2005/102259)。所述组合物特别适于治疗刺激。
在本发明的一些优选的实施例中,本发明组合包括组合物,该组合物包含外泌体以及羽扇豆油,优选地是甜味白色羽扇豆油,如国际申请WO98/47479中所述的甜味白色羽扇豆油。
在本发明的一些优选的实施例中,本发明组合包括组合物,该组合物包含外泌体以及玛卡肽提取物(见国际申请WO2004/112742)。所述组合物因其结瘢性质和抗老化性质而特别优选。
在本发明的一些优选的实施例中,本发明组合包括组合物,该组合物包含外泌体以及稻肽(见国际申请2008/009709)。所述组合物因其与刺激黑素形成和与黑色素转移相关的性质而特别优选。
在本发明的一些优选的实施例中,本发明组合包括组合物,该组合物包含外泌体以及循环神经酰胺(噁唑啉衍生物),如国际申请WO2004/050052、WO2004/050079和WO2004/112741中所述。所述组合物特别适于治疗炎症反应。
在本发明的一些优选的实施例中,本发明组合包括组合物,该组合物包含外泌体以及昆诺阿藜提取物,尤其肽提取物(见国际申请WO2008/080974)。所述组合物特别适于治疗炎性疾病和皮肤屏障修复。
在本发明的一些优选的实施例中,本发明组合包括组合物,该组合物包含外泌体以及古朴阿苏果油(cupuacu butter)。所述组合物因其润湿性质而特别优选。
在本发明的一些优选的实施例中,本发明组合包括组合物,该组合物包含外泌体以及油菜籽油精华素(rapeseed oleodistillate)。
在本发明的一些优选的实施例中,本发明组合包括组合物,该组合物包含外泌体以及玉米油精华素(corn oleodistillate)。
除外泌体之外,全部这些组合包含至少一种其他活性化合物,并且可以包含如上所述的两种、三种、四种或更多种活性化合物。
除这些活性物质之外,单独或与上文提及的活性物质组合,本发明的外泌体可以与本领域技术人员已知的防晒活性物质如UVB和/或UVA滤光物或遮光物或任何无机和/或有机遮光物或滤光物组合使用,所述技术人员将根据所寻求的保护程度调整它们的选择和其浓度。
作为防晒活性物质的实例,可以具体提到二氧化钛、氧化锌、亚甲基双-苯并三唑基四甲基丁基酚(品牌名称:TINOSORB M)和双-乙基己氧苯酚甲氧苯基三嗪(品牌名称:TINOSORB S)、辛-水杨酸、丁基甲氧基二苯甲酰基甲烷、对苯二亚甲基二樟脑磺酸、4-甲基亚苄基樟脑、二苯酮、甲氧基肉桂酸乙基己酯、二甲基PABA乙基己酯和二乙基己基丁酰胺基三嗪酮。
在本发明的背景下术语“衰老”以及术语“皮肤衰老”用于描述皮肤外观上出现的可见变化以及那些通过触摸可察觉的可见变化,例如像,在非限制意义上的皱纹、细纹、粗糙、表情纹、妊娠纹、不连续性、深皱纹、松弛、皮肤下垂(如脸颊下垂、眼袋、双下巴)、毛孔大小的增加、失去弹性、失去回弹性、失去紧致性、弹性组织变性、异常分化、角化过度、角化病、皮肤颜色变化(如斑点、发红或眼袋)、色素沉着过度的区域的形成(如老年斑、黄褐斑、或雀斑)、失去柔滑性、橘皮样皮肤、失去胶原蛋白结构以及角质层、真皮、表皮、血管系统(例如蜘蛛静脉或毛细血管扩张的形成)、或靠近皮肤的这些组织的其他组织学变化。皮肤衰老是一个具有两个主要部分的过程,这两个主要部分为:时序衰老,这归因于时间的流逝;和光诱导的衰老,这归因于暴露于紫外线辐射的水平并且被称作光老化。若干环境因素如暴露于烟草烟雾、暴露于污染、以及气候条件(如寒冷和/或风)的总和也促成了皮肤衰老。在本发明的背景中,“皮肤抗衰老治疗”为一种用于防止、延迟、和/或减轻人类皮肤衰老的治疗。
相比现有技术,本发明的技术效果如下:
本发明提供了胎体来源的外泌体在皮肤调节产品中的用途,通过实验证实,该外泌体能够通过促进细胞胶原蛋白表达、增加细胞肌原纤蛋白合成、维持干细胞干性以及刺激干细胞增殖实现抗衰老功能;能够通过抑制角质形成细胞中炎症介质或基质蛋白酶的基因表达的产品、以及抑制角质形成细胞中VEGF合成和释放实现对抗痤疮的药学功能;能够通过促进毛囊乳头成纤维细胞中ATP合成或增强线粒体代谢活性的产品、增加微毛囊的细胞存活力或减轻微毛囊膜损伤,实现增强毛囊、抗脱发的皮肤病学用途;能够通过增加抗氧化酶NQO1和GSTT1的表达实现清除和排除毒素;通过增加天然免疫因子的皮肤抗微生物肽hBD3的表达实现对皮肤的保护;以及通过增加抗氧化蛋白GPX1、过氧化氢酶、TRX1和PRDX1的表达来实现抑制活性氧的产生,进而可以用作预防由亚洲沙尘(PM2.5)引起的皮肤问题、保护皮肤以及预防和治疗皮肤老化的药物组合物或美容组合物。因此,本发明为抗衰老皮肤护理、痤疮对抗、防脱发、防亚洲沙尘影响等皮肤护理提供了一种新的途径。
附图说明
图1为本发明胎体来源外泌体的电镜检测结果;
图2为NTA检测的外泌体粒径分布结果。
具体实施方式
以下实施例、实验例对本发明进行进一步的说明,不应理解为对本发明的限制,同时实施例不包括对传统方法的详细描述。在下述实施例中,多组间的比较统计学以方差分析及组间检验计算P值,仅有两组时以非参数T检验计算P值,多个率的比较以卡方检验计算P指。
实施例1、胎羊血清外泌体的制备
将4月龄高山黑绵羊胎羊血清用0.45μm滤膜过滤,在4℃,1000g离心10min,收集上清;收集的上清液4℃,2000g离心20min,收集上清;收集的上清液4℃,10000g离心30min,收集上清;收集的上清液,110000g离心90min,弃上清,使用磷酸盐缓冲液重悬沉淀;再次110000g离心90min,弃上清,少量磷酸盐缓冲液重悬沉淀,0.45μm滤膜过滤,得到外泌体。用Bradford法检测外泌体总蛋白量(Bio-Rad Protein Assay Reagent)。外泌体冻干后储存于-80℃。成年羊血清用同样的方法提取外泌体,作为对照外泌体。
实施例2、胎骆驼血清外泌体的制备
将11月龄澳洲羊驼血清用0.45μm滤膜过滤,在4℃,1000g离心10min,收集上清;收集的上清液4℃,2000g离心20min,收集上清;收集的上清液4℃,10000g离心30min,收集上清;收集的上清液,110000g离心90min,弃上清,使用磷酸盐缓冲液重悬沉淀;再次110000g离心90min,弃上清,少量磷酸盐缓冲液重悬沉淀,0.45μm滤膜过滤,得到外泌体。用Bradford法检测外泌体总蛋白量(Bio-Rad Protein Assay Reagent)。外泌体冻干后储存于-80℃。成年羊驼血清用同样的方法提取外泌体,作为对照外泌体。
实施例3、胎牛血清外泌体的制备
将8月龄澳洲胎牛血清用0.22μm无菌膜过滤,在4℃,1000g离心10min,收集上清;收集的上清液4℃,2000g离心20min,收集上清;收集的上清液4℃,10000g离心30min,收集上清;收集的上清液,110000g离心90min,弃上清,使用磷酸盐缓冲液重悬沉淀;再次110000g离心90min,弃上清,少量磷酸盐缓冲液重悬沉淀,0.45μm滤膜过滤,得到外泌体。用Bradford法检测外泌体总蛋白量(Bio-Rad Protein Assay Reagent)。外泌体冻干后储存于-80℃。
实施例4、胎羊肝脏外泌体的制备
将4月龄高山黑绵羊胎羊肝脏经磷酸盐缓冲液(PBS)反复冲洗后,剪成直径约1-2mm的组织块;经2型胶原酶和胰酶消化依次后,将上清液离心,取细胞沉淀放入培养瓶,使用含10%胎牛血清DMEM/F12培养基,5%CO2、37℃饱和湿度培养;去除非贴壁细胞,在贴壁细胞80%融合后更换无血清培养基培养48h;收集培养上清液;0.45μm滤膜过滤得到富含外泌体的培养液。
将培养液在4℃,1000g离心10min,收集上清;收集的上清液4℃,2000g离心20min,收集上清;收集的上清液4℃,10000g离心30min,收集上清;收集的上清液,110000g离心90min,弃上清,使用磷酸盐缓冲液重悬沉淀;再次110000g离心90min,弃上清,少量磷酸盐缓冲液重悬沉淀,0.45μm滤膜过滤,得到外泌体。
实施例5、外泌体生化表征检测
照以下步骤进行外泌体电镜检测:将实施例1中得到的胎羊血清来源的外泌体解冻后用缓冲液重悬得到样品;将样品滴于带有支持膜的铜网上;将染液与样品进行混匀得到混匀液,待铜网上的悬液稍微干燥后将混匀液滴于铜网上,负染2分钟后自然风干;在透射电镜下观察。观察到符合外泌体30-150nm形态特征的双层膜囊泡(图1)。经ELISA检测,外泌体表达CD63,CD81和Alix。
利用NanoFCM Flow NanoAnalyzer(纳米粒径分析仪)对实施例1中得到的胎羊血清来源的外泌体进行粒径检测方法,具体包括以下步骤:
粒径检测:粒径标准品、空白对照和待测样品(子宫腔液)均需要在相同检测条件下(激光功率和散射通道衰减系数完全相同)采样;所有样品均在较低进样压力下(取样不大于1.0kPa)检测;在合适的条件下检测粒径标准品(粒径最小的硅球的散射光信号与背景完全分开且最大的硅球信号未饱和,检测器饱和值为3.6k);检测重悬待测样品用的缓冲液,用于扣除背景颗粒,作为空白对照;检测待测样品,若待测样品中20%以上的颗粒在散射通道的信号强度达到饱和,则表明当前的粒径标准品不是该样品粒径表征的最优选择;经上述步骤检测到样品中的粒径大部分集中在85nm左右,符合外泌体直径30-150nm范围,说明检测到的样品为外泌体,如图2。
实施例6、外泌体增强1型胶原蛋白
将实施例1所述胎羊血清外泌体(0.02%质量体积比)加入到人成纤维细胞的培养液(DMEM培养液,1%抗生素)中,以证实外泌体在细胞水平上促进1型胶原蛋白合成。合成的胶原蛋白的测定是使用PICP试剂盒(前胶原蛋白I型C肽酶免疫测定试剂盒)而进行定量。使用人成纤维细胞培养液将人源成纤维细胞(human fibroblast)以2×105个细胞/孔等分到6孔版中。确认细胞粘附后,将作为有效成分的胎羊血清外泌体溶解于培养液,对照组利用浓度一致的成年羊血清外泌体,空白组不添加任何外泌体,仅培养液。在37℃、5%CO2条件的培养箱中培养24小时后,测定细胞裂解物中I型胶原蛋白的含量,其结果如表1所示,结果显示胎羊血清外泌体可以促进胶原蛋白表达。
表1.胶原蛋白浓度
处理组 | 对照组 | 空白组 | |
1型胶原蛋白浓度μg/ml | 0.018 | 0.001 | 0.001 |
增加率(%,较对照组) | 1800 | - |
实施例7.外泌体对人造皮肤影响
利用实施例2所述胎骆驼血清外泌体、对照外泌体进行本实施例。
通过紫外线照射进行了光衰老的皮肤的情况下,表皮-真皮结合部位的胶原纤维网络受损。因此,胶原纤维的量和形态用作皮肤光衰老的指标。利用实施例2所述胎骆驼血清外泌体进行本实施例。以含有0.02%来自成年骆驼血清外泌体作为对照(对照)。空白组不添加任何外泌体,仅培养液。涂布后,将接受紫外线照射的无毛小鼠的皮肤组织用马松三色法(Masson's Trichrome)染色,用光学显微镜观察检测染色面积,相对于对照组的染色面积为标准,结果如表2。
表2相对染色面积
平均值 | SD | p值 | |
对照[0.02%(w/v培养基)成年骆驼血清外泌体] | 100 | 10.5 | |
空白组[不添加任何外泌体] | 98.61 | 6.7 | P>0.05 |
实施例1所述胎骆驼血清外泌体0.02%(w/v培养基) | 155.1 | 18.5 | p<0.05 |
进一步的,购买人造皮肤(来自MatTek,Ashland,USA的EpiDermFTTM)后,在专用培养基(EFT-400)中稳定18小时。在人造皮肤的表面上,涂布浓度为0.02%(质量体积比)的100μl的实施例1所述胎羊血清外泌体作为有效成分。以含有1%来自成年羊血清外泌体作为对照(对照)。空白组不添加任何外泌体,仅培养液。24小时后,将人造皮肤组织用10%甲醛固定,并用石蜡包埋,用马松三色法(Masson's Trichrome:M&T)染色并切成5μm的组织,从而观察计算胶原纤维(collagen fibers)的染色面积,结果如表3。
表3相对染色面积
平均值 | SD | p值 | |
对照[0.02%(w/v培养基)成年羊血清外泌体] | 100 | 12.5 | |
空白组[不添加任何外泌体] | 102.42 | 7.5 | P>0.05 |
实施例1所述胎羊血清外泌体0.02%(w/v培养基) | 148.61 | 16.1 | p<0.05 |
这些结果显示,根据本发明的所述的外泌体对具有抗光衰老作用。
实施例8.外泌体增强间充质干细胞ALDH表达。
利用实施例1所述胎羊血清外泌体、对照外泌体进行本实施例。
将人骨髓来源的间充质干细胞(MSC),以2×105个细胞/孔等分到6孔版中。确认细胞粘附后,将作为有效成分的胎羊血清外泌体溶解于培养液,对照组利用成年羊血清外泌体,各孔外泌体均为200μg/ml的浓度。空白组不添加任何外泌体,仅培养液。在37℃、5%CO2条件的培养箱中培养24小时后,利用流式细胞术检测MSC细胞的ALDH阳性率和Ki67阳性率,其结果如表4。
表4.ALDH阳性率和Ki67阳性率
结果显示胎羊血清外泌体具有非常强的维持干细胞干性和刺激干细胞增殖的作用。
实施例9.外泌体对预防和治疗痤疮的作用
利用实施例1所述胎羊血清外泌体、对照外泌体进行本实施例。空白组不添加任何外泌体,仅培养基。角质形成细胞单层模型:L-1α、IL-1β、IL-8、MMP-2和MMP-9表达的研究、角质形成细胞/痤疮丙酸杆菌共培养模型:MMP-9表达的研究、角质形成细胞单层模型:对IL-1α和VEGF的作用研究、角质形成细胞/痤疮丙酸杆菌共培养模型:对IL-8产生的作用研究的模型建立、实验方法、实时RT-PCR方法和结果计算参考专利(CN102481245B)。结果如下:
A.外泌体对初始炎症介质:IL-1α和IL-1β的影响。分析编码IL-1α和IL-1β的基因的表达。
在48小时处理后,测试的0.02%和0.05%外泌体显著抑制角质形成细胞中的IL-1α基因表达(表5)和IL-1β基因表达(表6)。
表5:角质形成细胞中的IL-1α基因表达
IL-1α分析 | RQ | 抑制% | p值 |
对照 | 1 | ||
空白 | 0.98 | ||
0.02%外泌体 | 0.41 | -59 | p<0.05 |
0.05%外泌体 | 0.16 | -84 | p<0.05 |
表6:角质形成细胞中的IL-1β基因表达
IL-1β分析 | RQ | 抑制% | p值 |
对照 | 1 | ||
空白 | 1.05 | ||
0.02%外泌体 | 0.25 | -75 | p<0.05 |
0.05%外泌体 | 0.07 | -93 | p<0.01 |
B.外泌体对IL-8表达的影响:次级炎症介质
1.分析编码IL-8的基因的表达
在48小时处理后,测试的0.02%和0.05%外泌体显著抑制角质形成细胞中的IL-8基因表达(表7)。
表7:角质形成细胞中的IL-8基因表达
IL-8分析 | RQ | 抑制% | p值 |
对照 | 1 | ||
空白 | 1.02 | ||
0.02%外泌体 | 0.26 | -74 | p<0.05 |
0.05%外泌体 | 0.15 | -85 | p<0.01 |
2.对受到痤疮丙酸杆菌刺激的角质形成细胞中IL-8产生的影响。
用痤疮丙酸杆菌悬液处理角质形成细胞极强烈地刺激IL-8释放,一种炎症次生标记(表8)。用外泌体预处理60分钟抑制了角质形成细胞释放IL-8。IL-8生产的抑制在0.02%开始并且在0.1%达到完全。
表8:分析角质形成细胞/痤疮丙酸杆菌共培养物中的IL-8
C.外泌体对基质蛋白酶MMP-2和MMP-9的影响
1.MMP-2表达的分析
用0.05%外泌体处理角质形成细胞48小时导致MMP-2基因表达的显著抑制(-75%抑制)(表9)。
表9:角质形成细胞中的MMP-2基因表达
MMP-2 | RQ | 抑制% | p值 |
对照 | 1 | ||
空白 | 0.98 | ||
0.05%外泌体 | 0.167 | -83 | p<0.01 |
2.MMP-9表达的分析
在参与痤疮病理的基质蛋白酶当中,MMP-9发挥特别重要的作用。实际上,这种蛋白酶受促炎性细胞因子正调节,还受痤疮丙酸杆菌正调节。
如表10中所示,Q-PCR结果的分析显示用外泌体处理48小时后抑制角质形成细胞中的MMP-9基因表达(在0.02%时-49%抑制和在0.05%时-72%抑制)。
表10:角质形成细胞中的MMP-9基因表达
MMP-9 | RQ | 抑制% | p值 |
对照 | 1 | ||
空白 | 1.02 | ||
0.02%外泌体 | 0.51 | -49 | p<0.01 |
0.05%外泌体 | 0.28 | -72 | p<0.01 |
类似地,还在角质形成细胞/痤疮丙酸杆菌共培养模型中评价对MMP-9表达的调节(表11)。
使用这个模型,展示了痤疮丙酸杆菌细菌悬液对MMP-9基因表达的刺激性影响(+67%)。
相反,用外泌体预处理角质形成细胞对抗衰老丙酸杆菌的这种刺激性作用并且还抑制这种刺激性作用(相对于用细菌悬液处理的角质形成细胞,-57%和-71%)。
表11:角质形成细胞/痤疮丙酸杆菌共培养物中的MMP-9基因表达
D.外泌体对血管发生(VEGF)的影响
最后,研究了外泌体对角质形成细胞合成和释放VEGF的潜在抑制性影响。结果呈现于表12中。
因而,PMA刺激角质形成细胞24小时诱导VEGF的大量和明显释放(+226%)。相反,用外泌体预处理角质形成细胞24小时对这种作用并且显著地抑制这种作用。
表12:分析角质形成细胞中的VEGF
实施例10.胎猪胃来源外泌体的制备
将3月龄胎猪胃经磷酸盐缓冲液(PBS)反复冲洗后,剪成直径约1-2mm的组织块;经2型胶原酶和胰酶消化依次后,将上清液离心,取细胞沉淀放入培养瓶,使用含10%胎牛血清DMEM/F12培养基,5%CO2、37℃饱和湿度培养;去除非贴壁细胞,在贴壁细胞80%融合后更换无血清培养基培养48h;收集培养上清液;0.45μm滤膜过滤得到富含外泌体的培养液。
将培养液在4℃,1000g离心10min,收集上清;收集的上清液4℃,2000g离心20min,收集上清;收集的上清液4℃,10000g离心30min,收集上清;收集的上清液,110000g离心90min,弃上清,使用磷酸盐缓冲液重悬沉淀;再次110000g离心90min,弃上清,少量磷酸盐缓冲液重悬沉淀,0.45μm滤膜过滤,得到外泌体。
实施例11.新生羊胃液来源外泌体的制备
将新生黑绵羊胎胃液用0.45μm滤膜过滤,在4℃,1000g离心10min,收集上清;收集的上清液4℃,2000g离心20min,收集上清;收集的上清液4℃,10000g离心30min,收集上清;收集的上清液,110000g离心90min,弃上清,使用磷酸盐缓冲液重悬沉淀;再次110000g离心90min,弃上清,少量磷酸盐缓冲液重悬沉淀,0.45μm滤膜过滤,得到外泌体。用Bradford法检测外泌体总蛋白量(Bio-Rad Protein Assay Reagent)。外泌体冻干后储存于-80℃。
实施例12:外泌体增强V型胶原蛋白表达
利用实施例1所述胎羊血清外泌体、实施例4所述胎羊肝脏外泌体进行本实施例。
正常人成纤维细胞在添加不同终浓度的各种外泌体的FGM培养基中培养48小时,然后除去细胞培养基。添加0.05%来自成年羊血清外泌体的相同培养基用作对照(对照)。空白组不添加任何外泌体,仅培养液。将细胞层用氢氧化铵溶液裂解,然后用在缓冲溶液(PBS)中稀释至1/4000的抗-胶原蛋白V抗体测定V型胶原蛋白。60分钟后,应用稀释至1/25000的二级抗体达60分钟。在洗涤后,加入显示溶液,测定荧光(ENVision,PerkinElmer)。将荧光结果相对于对照培养基得到的荧光(对照)进行标准化,使其与在每个条件下得到的胶原蛋白量相关。所示结果为3次测定的平均值(n=3)(SD:标准偏差)。结果如表13。
表13 V型胶原蛋白表达情况
平均值 | SD | p值 | |
对照[0.05%(w/v培养基)成年羊血清外泌体] | 100.54 | 8.4 | |
空白 | 96.81 | 7.51 | P>0.05 |
实施例1所述胎羊血清外泌体0.02%(w/v培养基) | 122.66 | 16.64 | p<0.05 |
实施例1所述胎羊血清外泌体0.05%(w/v培养基) | 195.55 | 24.32 | p<0.01 |
实施例4所述胎羊肝脏外泌体0.02%(w/v培养基) | 135.15 | 123.6 | p<0.05 |
实施例4所述胎羊肝脏外泌体0.05%(w/v培养基) | 175.68 | 29.8 | p<0.05 |
结论:在所分析的成纤维细胞中,所述外泌体使V型胶原蛋白表达增加至少22%和35%,显示了外泌体在增强胶原蛋白表达的性质,可以用于增强毛囊和减少脱发方面的性质。
实施例13:外泌体增加肌原纤蛋白-1合成
将正常人成纤维细胞在FGM培养基中培养48小时,然后用实施例1所述胎羊血清外泌体、实施例2所述胎骆驼血清外泌体处理细胞,最终重量浓度相对于培养基的最终体积为0.02%或0.05%。采集细胞,然后用裂解缓冲液裂解以进行免疫印迹法(Western Blots)。通过BCA方法测定了蛋白质浓度。将所有样品相对于蛋白质总量进行标准化(n=3)。使用抗-肌原纤蛋白-1抗体(LS-BIO),因为是过氧化物酶-偶联的二级抗体。化学发光底物使得能够说明信号并对其进行定量(Protein Simple),结果如表14。
表14肌原纤蛋白-1表达
平均值 | SD | p值 | |
对照[0.05%(w/v培养基)成年羊血清外泌体] | 100.31 | 6.45 | |
空白 | 105.25 | 10.15 | P>0.05 |
实施例1所述胎羊血清外泌体0.02%(w/v培养基) | 184.65 | 17.61 | p<0.05 |
实施例1所述胎羊血清外泌体0.05%(w/v培养基) | 266.14 | 20.12 | p<0.05 |
实施例2所述胎骆驼血清外泌体0.02%(w/v培养基) | 159.68 | 19.85 | p<0.05 |
实施例2所述胎骆驼血清外泌体0.05%(w/v培养基) | 233.12 | 29.63 | p<0.05 |
结论:与对照相比和,本发明所述外泌体显示出在成纤维细胞中的肌原纤蛋白-1合成增加。
实施例14:外泌体促进毛囊乳头成纤维细胞中ATP合成增加
将来自毛囊乳头的非病理性人成纤维细胞在DMEM培养基上培养24小时,然后用实施例1所述胎羊血清外泌体、实施例2所述胎骆驼血清外泌体处理细胞处理6天,终浓度/体积相对于培养基总体积而言为0.02%或0.05%体积。在6天后通过酶促法(荧光素/荧光素酶络合物;ATPBioluminescence kit Roche Diagnostics)测量ATP含量(表15)。
表15 ATP含量
平均值 | SD | p值 | |
对照[0.05%(w/v培养基)成年羊血清外泌体] | 100.64 | 11.31 | |
空白 | 94.25 | 4.65 | |
实施例1所述胎羊血清外泌体0.02%(w/v培养基) | 145 | 16.65 | p<0.05 |
实施例1所述胎羊血清外泌体0.05%(w/v培养基) | 167 | 19.18 | p<0.05 |
实施例2所述胎骆驼血清外泌体0.02%(w/v培养基) | 135 | 15.95 | p<0.05 |
实施例2所述胎骆驼血清外泌体0.05%(w/v培养基) | 157 | 20.33 | p<0.01 |
结论:外泌体与对照相比显示出ATP合成增加,证实其用于增强毛囊的活性的用途。
实施例15:外泌体增强毛乳头成纤维细胞的线粒体代谢活性
将毛囊乳头的非病理性人成纤维细胞培养24小时,实施例1所述胎羊血清外泌体、实施例2所述胎骆驼血清外泌体处理细胞处理6天,终浓度/体积相对于培养基总体积而言为0.02%和0.05%。在琥珀酸脱氢酶的存在下、通过MTT(3-[4,5-二甲基噻唑-2-基]-2,5-二苯基四唑鎓溴化物)的还原测量了成纤维细胞的线粒体活性。将所得沉淀物用DMSO提取,然后于540nm测量DMSO溶液的光密度(表16)。
表16相对线粒体活性
平均值 | SD | p值 | |
对照[0.05%(w/v培养基)成年羊血清外泌体] | 100 | 10 | |
实施例1所述胎羊血清外泌体0.02%(w/v培养基) | 115 | 12 | p<0.05 |
实施例1所述胎羊血清外泌体0.05%(w/v培养基) | 154 | 14 | p<0.05 |
实施例2所述胎骆驼血清外泌体0.02%(w/v培养基) | 126 | 14 | p<0.05 |
实施例2所述胎骆驼血清外泌体0.05%(w/v培养基) | 171 | 16 | p<0.05 |
结论:本发明所述外泌体与对照相比显示出毛囊乳头成纤维细胞的线粒体活性增加。该线粒体活性参与毛囊的增强。
实施例16:外泌体对微毛囊的作用
微毛囊重建方法:微毛囊模型包括将乳头成纤维细胞、来自毛囊外鞘的角质形成细胞和黑素细胞在三维上共培养。由于能够整合各种细胞类型之间的神经-表皮-间质相互作用,该细胞模型构成了最接近毛囊的重建器官模型。
将非病理性乳头成纤维细胞培养3天。然后,将黑素细胞和毛囊外鞘的角质形成细胞加入到新型乳头中以形成微毛囊。培养24小时后,加入实施例1所述胎羊血清外泌体,终浓度相对于培养基总体积而言为0.05%体积。将相同的培养基在成年羊血清外泌体的情况下培养(对照)。处理48小时后,对培养基和微毛囊采样用于分析。
通过PrestoBlue方法(Thermo Fisher Scientific)测量了微毛囊的细胞存活力。处理48小时后进行测定。值表示为对照进行标准化后的平均值%(表17)。
表17相对细胞活力
平均值 | SD | p值 | |
对照[0.05%(w/v培养基)成年羊血清外泌体] | 100.65 | 7.81 | |
空白 | 101.11 | 3.51 | P>0.05 |
实施例1所述胎羊血清外泌体0.05%(w/v培养基) | 156 | 20.1 | p<0.05 |
结论:本发明所述外泌体具有增加微毛囊的细胞存活力的能力,使其成为对增强毛囊具有活性的外泌体。
进一步评估微毛囊水平上的膜损伤的减轻
利用乳酸脱氢酶检测法,通过比色法测量细胞损伤,使得能够基于培养基中受损细胞中乳酸脱氢酶活性的测量来定量细胞损伤。细胞膜损伤的增加和细胞溶解导致乳酸脱氢酶活性增加,其与裂解细胞的数量成比例。处理48小时后,在培养基中进行了乳酸脱氢酶活性测量(表18)。
表18相对细胞损伤
平均值 | SD | p值 | |
对照[0.05%(w/v培养基)成年羊血清外泌体] | 100.33 | 10.6 | |
空白 | 89.91 | 9.91 | P>0.05 |
实施例1所述胎羊血清外泌体0.05%(w/v培养基) | 47 | 6.7 | p<0.05 |
结论:本发明的外泌体具有减轻膜损伤的能力,使其成为对增强毛囊具有活性的本发明外泌体,增强毛囊促进了脱发的减少。
实施例17:外泌体应对亚洲沙尘引起的人角质形成细胞中的活性氧产生
亚洲沙尘是起源于我国、蒙古、中亚和俄罗斯等国沙漠的一种气候现象。在这些地方,沙子或黄色沙尘随风刮向东并落到地上。几乎每年春季北京等北方地区都会受到亚洲沙尘的影响。亚洲沙尘包含有机和无机物质,并且其物理性质和组成是不同的。其甚至包含可能具有生物效应的金属。亚洲沙尘中包含的大颗粒保留在原地或其周围,而直径为10μm或更小的微粒(颗粒物10;PM10),近年来持续爆发的PM2.5也属于这类气候污染。
据报道,微粒在被吸入时可以深入到达亚段支气管和肺的气体交换区域并可能损伤呼吸系统(Yanagisawa et al,.Exp Biol Med232:1109-1118,2007;Kim et al,.JBiosci28(1):77-81,2003)。亚洲沙尘对人呼吸疾病方面的健康影响作已经有大量报道。在小鼠实验性研究中,在被灌注亚洲沙尘的小鼠肺中发现氧化应激相关指数增大(Naota etal.,Toxicol Pathol.2010 Sep30。临床上,如果皮肤直接暴露于亚洲沙尘,它可能通过过敏反应导致接触性皮炎。此外,已知干燥和强烈的亚洲沙尘暴通过使皮肤丧失水分导致皮肤干燥、角质化、瘙痒、痤疮、特应性等。近来,关于亚洲沙尘对皮肤的有害作用也有报道,如研究显示亚洲沙尘导致角质形成细胞中包括细胞因子白介素6和白介素8的促炎性因子的增加(Choi et al,.Toxicol Lett.15;200(1-2):92-9.2010)。
人表皮新生角质形成细胞细胞培养24小时,培养条件同Lonza公司说明书所述。然后用实施例1所述胎羊血清外泌体、实施例2所述胎骆驼血清外泌体处理细胞处理12小时,终浓度/体积相对于培养基总体积而言为0.02%或0.05%体积,然后加入,25μg/mL亚洲沙尘样品,并将每组细胞继续孵育24小时。亚洲沙尘样品是在亚洲沙尘季节期间在国贸三期A座大楼(北京市)的阳台屋顶上收集的。将细胞用10mL磷酸缓冲盐(phosphate bufferedsaline,PBS)洗涤两次,并使用Glomax20/20发光检测仪在加入1mM鲁米诺和20单位/mL辣根过氧化物酶(HRP)1分钟后在2mL PBS中测量化学发光。结果如表19
表19活性氧相对水平
平均值(%) | SD | p值 | |
未加入亚洲尘土空白对照 | 14.09 | 1.11 | |
对照[0.05%(w/v培养基)成年羊血清外泌体] | 100.01 | 5.45 | |
实施例1所述胎羊血清外泌体0.02%(w/v培养基) | 34.43 | 4.30 | p<0.05 |
实施例1所述胎羊血清外泌体0.05%(w/v培养基) | 21.83 | 1.86 | p<0.05 |
实施例2所述胎骆驼血清外泌体0.02%(w/v培养基) | 59.80 | 7.88 | p<0.05 |
实施例2所述胎骆驼血清外泌体0.05%(w/v培养基) | 15.62 | 2.33 | p<0.05 |
结果显示,本发明所述的胎体来源外泌体可以抑制由亚洲沙尘介导的正常人角质形成细胞中活性氧的产生。
实施例18:外泌体对毒素去毒和排除因子、抗微生物肽的表达作用
同实施例17,人表皮新生角质形成细胞细胞培养24小时,培养条件同Lonza公司说明书所述。然后用实施例1所述胎羊血清外泌体、实施例2所述胎骆驼血清外泌体处理细胞处理12小时,终浓度/体积相对于培养基总体积而言为0.02%和0.05%体积,然后加入,25μg/mL亚洲沙尘样品,并将每组细胞继续孵育24小时。亚洲沙尘样品是在亚洲沙尘季节期间在国贸三期A座大楼(北京市)的阳台屋顶上收集的。实验各组细胞用10mL磷酸盐缓冲液洗涤两次,并使用TRIzol(Invitrogen)从细胞中分离出总RNA(total RNA)。再次使用RNA试剂盒(Qiagen)对分离出的RNA进行纯化并使用Bioanalyzer2100(Agilent)分析RNA的质量(quality)。使用Superscript逆转录酶(RT)II试剂盒(Superscriptreversetranscriptase(RT)II kit)由分离出的RNA合成cDNA,并通过实时反转录聚合酶链反应(real-time reverse transcription polymerase chain reaction,qPCR)对cDNA进行定量分析。使用TaqMan基因表达分析试剂盒(TaqMan gene expression assay kit,A ppliedBiosys tems)对GSTT1(Hs00184475_m1)、NQO1(Hs01045994_m1)和hBD3(hs00218678_m1)的表达水平进行检测,结果如表20-22。
表20 NQO1相对表达水平
平均值(%) | SD | p值 | |
未加入亚洲尘土对照 | 125.54 | 28.60 | |
对照[0.05%(w/v培养基)成年羊血清外泌体] | 100.00 | 8.30 | |
实施例1所述胎羊血清外泌体0.02%(w/v培养基) | 212.14 | 14.95 | p<0.05 |
实施例1所述胎羊血清外泌体0.05%(w/v培养基) | 435.40 | 33.29 | p<0.05 |
实施例2所述胎骆驼血清外泌体0.02%(w/v培养基) | 245.63 | 14.17 | p<0.05 |
实施例2所述胎骆驼血清外泌体0.05%(w/v培养基) | 268.04 | 26.78 | p<0.05 |
表21 GSTT1相对表达水平
平均值(%) | SD | p值 | |
未加入亚洲尘土空白对照 | 393.75 | 64.08 | |
对照[0.05%(w/v培养基)成年羊血清外泌体] | 100.00 | 12.58 | |
实施例1所述胎羊血清外泌体0.02%(w/v培养基) | 333.11 | 18.79 | p<0.05 |
实施例1所述胎羊血清外泌体0.05%(w/v培养基) | 626.60 | 57.14 | p<0.05 |
实施例2所述胎骆驼血清外泌体0.02%(w/v培养基) | 331.97 | 33.29 | p<0.05 |
实施例2所述胎骆驼血清外泌体0.05%(w/v培养基) | 743.04 | 97.00 | p<0.05 |
表22 hBD3相对表达水平
平均值(%) | SD | p值 | |
未加入亚洲尘土对照 | 214.41 | 12.06 | |
对照[0.05%(w/v培养基)成年羊血清外泌体] | 100.00 | 9.23 | |
实施例1所述胎羊血清外泌体0.02%(w/v培养基) | 231.58 | 11.71 | p<0.05 |
实施例1所述胎羊血清外泌体0.05%(w/v培养基) | 558.07 | 36.40 | p<0.05 |
实施例2所述胎骆驼血清外泌体0.02%(w/v培养基) | 355.62 | 58.83 | p<0.05 |
实施例2所述胎骆驼血清外泌体0.05%(w/v培养基) | 602.69 | 93.68 | p<0.05 |
结果所示,本发明所述胎体外泌体可以增加去毒素蛋白NQO1、天然免疫因子的皮肤抗微生物肽hBD3和排除毒素的酶的GSTT1在正常人角质形成细胞中的表达。
实施例19:外泌体对抗氧化蛋白基因的表达作用
同实施例17,人表皮新生角质形成细胞细胞培养24小时,培养条件同Lonza公司说明书所述。然后用实施例1所述胎羊血清外泌体、实施例2所述胎骆驼血清外泌体处理细胞处理12小时,终浓度/体积相对于培养基总体积而言为0.02%和0.05%体积,然后加入,25μg/mL亚洲沙尘样品,并将每组细胞继续孵育24小时。亚洲沙尘样品是在亚洲沙尘季节期间在国贸三期A座大楼(北京市)的阳台屋顶上收集的。实验各组细胞用10mL磷酸盐缓冲液洗涤两次,并使用TRIzol(Invitrogen)从细胞中分离出总RNA(total RNA)。再次使用RNA试剂盒(Qiagen)对分离出的RNA进行纯化并使用Bioanalyzer2100(Agilent)分析RNA的质量(quality)。使用Superscript逆转录酶(RT)II试剂盒(Superscriptreversetranscriptase(RT)II kit)由分离出的RNA合成cDNA,并通过实时反转录聚合酶链反应(real-time reverse transcription polymerase chain reaction,qPCR)对cDNA进行定量分析。使用TaqMan基因表达分析试剂盒(TaqMan gene expression assay kit,A ppliedBiosystems)对GPX1(Hs00829989_gH)、过氧化氢酶(Hs00156308_m1)、TRX1(Hs01555212_g1)和PRDX1(Hs00602020_mH)的表达水平进行检测,结果如表。
表23 GPX1相对表达水平
表24过氧化氢酶相对表达水平
平均值(%) | SD | p值 | |
未加入亚洲尘土对照 | 223.01 | 35.55 | |
对照[0.05%(w/v培养基)成年羊血清外泌体] | 100.00 | 13.74 | |
实施例1所述胎羊血清外泌体0.02%(w/v培养基) | 187.03 | 21.26 | p<0.05 |
实施例1所述胎羊血清外泌体0.05%(w/v培养基) | 426.89 | 71.06 | p<0.05 |
实施例2所述胎骆驼血清外泌体0.02%(w/v培养基) | 248.91 | 17.20 | p<0.05 |
实施例2所述胎骆驼血清外泌体0.05%(w/v培养基) | 533.55 | 88.82 | p<0.05 |
表25 TRX1相对表达水平
平均值(%) | SD | p值 | |
未加入亚洲尘土对照 | 153.48 | 20.96 | |
对照[0.05%(w/v培养基)成年羊血清外泌体] | 100.00 | 15.18 | |
实施例1所述胎羊血清外泌体0.02%(w/v培养基) | 196.10 | 14.93 | p<0.05 |
实施例1所述胎羊血清外泌体0.05%(w/v培养基) | 276.73 | 41.74 | p<0.05 |
实施例2所述胎骆驼血清外泌体0.02%(w/v培养基) | 155.23 | 20.53 | p<0.05 |
实施例2所述胎骆驼血清外泌体0.05%(w/v培养基) | 377.66 | 41.67 | p<0.05 |
表26 PRDX1相对表达水平
结果所示,本发明所述胎体外泌体可以增加清除活性氧的抗氧化酶GPX1、过氧化氢酶、TRX1和PRDX1的相对表达水平。有效对抗亚洲尘土介导的氧化应激反应。
实施例20:抗衰老实例
按照质量百分数,本发明实施例1所述的述胎羊血清外泌体1.2%,丁二醇5%,防腐剂0.2%以及0.6%氯化钠,水93%,分别称取适量各原料组分。将上述原料组分混合,即得抗衰老护肤水。
选择志愿者20名,性别随机。将志愿者随机分为2组,并分别随机在每位志愿者的左脸颊或右脸颊中的一侧脸颊,以及左眼角和右眼角中的一侧眼角使用本发明抗衰护肤水,并作为实验组;志愿者未使用抗衰护肤水的一侧脸颊和眼角作为对照组。
志愿者者于每日早晚各涂一次本发明抗衰老化妆品,每次涂用30分钟后以清水洗面。使用周期为4周,在测试周期内不得使用其他化妆品。然后,采用皮肤弹性测试仪和脸部皱纹成像仪,对比分析本发明抗衰老化妆品对志愿者皮肤弹性和皱纹改善情况,结果如下:
实施例21:化妆品制剂的实例
本发明人在下文提供几种用于局部施加、尤其适用于美容的组合物。
(1)清洁霜
原料/品牌名称 | % |
纯水 | QSP100% |
阿拉同恩(Arlatone) | 10%-30% |
椰油基葡糖苷 | 5%-20% |
羟丙基瓜尔胶 | 1%-5% |
辛酰甘氨酸 | 0%-2% |
防腐剂 | 0%-2% |
香料 | 0%-1% |
柠檬酸 | 0%-1% |
锌PCA | 0%-1% |
胎羊血清外泌体 | 0.01%-0.1% |
(2)调节皮脂的抗衰老乳剂
(3)抗炎性促愈合乳剂
原料/品牌名称 | % |
PEG40硬脂酸酯 | 1%-5% |
PEG5硬脂酸甘油 | 1%-5% |
地蜡 | 1%-5% |
单硬脂酸甘油酯 | 1%-5% |
失水山梨醇硬脂酸酯 | 0%-2% |
鲸蜡醇 | 0%-2% |
苹果酸氢酯醇 | 5%-20% |
维生素E | 0%-1% |
维生素B3 | 1%-5% |
玛卡肽提取物 | 1%-5% |
胎骆驼肝脏外泌体 | 0.01%-0.1% |
丁二醇 | 1%-5% |
吡罗克酮乙醇胺 | 0%-1% |
防腐剂 | 0%-1% |
甘油 | 1%-10% |
黄原胶 | 0%-1% |
锌PCA | 0%-2% |
米淀粉 | 1%-5% |
尼龙6 | 0%-2% |
聚丙烯酰胺凝胶 | 1%-5% |
维生素B6 | 0%-1% |
香料 | 0%-1% |
纯水 | QSP100% |
(4)修复性抗衰老乳剂
(5)调节角质层的抗衰老乳剂
(6)抗老化抗皱乳剂
(7)抗细菌抗衰老滚搽棒(stickroll-on)
原料/品牌名称 | % |
蓖麻油 | QSP100% |
油醇 | 10%-20% |
棕榈油 | 10%-20% |
聚甘油-3-蜂蜡 | 10%-20% |
小烛树蜡 | 10%-20% |
锂蒙脱石 | 10%-20% |
二氧化钛 | 0%-5% |
胎羊血清外泌体 | 0.01%-0.1% |
雪亚脂 | 0%-5% |
维生素E | 0%-1% |
(8)SPF 50+抗衰老防晒霜
(9)SPF 50+抗衰老防晒喷雾剂
(10)擦剂
原料/品牌名称 | % |
Arlatone duo(阿拉同恩多) | 5%-20% |
表皮剥脱剂 | 1%-10% |
小核菌胶 | 1%-10% |
防腐剂 | 0%-1% |
辛酰甘氨酸 | 0%-1% |
苏打 | 0%-1% |
胎牛血清外泌体 | 0.01%-0.1% |
多价螯合剂 | 0%-1% |
柠檬酸 | 0%-1% |
纯水 | QSP100% |
香料 | 0%-1% |
本发明中涉及的未说明部分与现有技术相同或采用现有技术加以实现。申请人声明,本发明通过上述实施例来说明本发明的详细方法,但本发明并不局限于上述详细方法,即不意味着本发明必须依赖上述详细方法才能实施。所属技术领域的技术人员应该明了,对本发明的任何改进,对本发明产品各原料的等效替换及辅助成分的添加、具体方式的选择等,均落在本发明的保护范围和公开范围之内。
Claims (8)
1.胎体来源的外泌体在皮肤调节产品中的用途,其特征在于,所述胎体指的是非人胎体。
2.根据权利要求1所述的胎体来源的外泌体在制备皮肤调节产品中的用途,其特征在于:
其中,所述外泌体提取自非人胎生动物胎体、非人新生体内脏器或生理性流体内。
3.根据权利要求2所述的胎体来源的外泌体在制备皮肤调节产品中的用途,其特征在于:
其中,所述非人胎生动物胎体为非人胎生动物母体内的幼体和新出生动物;所述非人新生体内脏器为自然分娩后24小时内的新生动物的肝脏或骨髓;所述生理性流体包括非人新生体的血液、血浆或血清。
4.根据权利要求1所述的胎体来源的外泌体在制备皮肤调节产品中的用途,其特征在于:
其中,所述皮肤调节产品包括抗衰老或增强皮肤弹性的护肤产品、皮肤病学用途产品以及预防由亚洲沙尘引起的皮肤问题的护肤产品;
所述皮肤调节产品的形态包括直接涂抹式护肤产品或口服式皮肤调理产品。
5.根据权利要求4所述的胎体来源的外泌体在制备皮肤调节产品中的用途,其特征在于:
其中,所述皮肤病学用途产品为对抗痤疮或增强毛囊、抗脱发的皮肤病学用途产品;
所述预防由亚洲沙尘引起的皮肤问题的护肤产品为清除和排除皮肤毒素的产品、增强皮肤免疫性的产品或抑制活性氧的产生的产品;
所述口服式皮肤调理产品包括含有该外泌体的乳制品、基于脂肪制品、饮料制品或谷物制品。
6.根据权利要求5所述的胎体来源的外泌体在制备皮肤调节产品中的用途,其特征在于:
其中,所述抗衰老或增强皮肤弹性的护肤产品为促进细胞胶原蛋白表达、增加细胞肌原纤蛋白合成、维持干细胞干性以及刺激干细胞增殖的护肤产品中的一种或多种组合;
所述对抗痤疮的皮肤病学用途产品为抑制角质形成细胞中炎症介质或基质蛋白酶的基因表达的产品、以及抑制角质形成细胞中VEGF合成和释放产品中的一种或两种组合;
所述增强毛囊、抗脱发的皮肤病学用途产品为促进毛囊乳头成纤维细胞中ATP合成或增强线粒体代谢活性的产品、增加微毛囊的细胞存活力或减轻微毛囊膜损伤产品中的任意一种或两种;
所述清除和排除皮肤毒素的产品为增强抗氧化酶NQO1和GSTT1表达的产品;
所述增强皮肤免疫性的产品为增加天然免疫因子皮肤抗微生物肽hBD3表达的产品;
所述抑制活性氧产生的产品为增加抗氧化蛋白GPX1、过氧化氢酶TRX1和PRDX1表达的产品。
7.根据权利要求1所述的胎体来源的外泌体在皮肤调节产品中的用途,其特征在于,该外泌体的制备方法如下:
A、原料处理:通过下述(1)或(2)中的处理方式进行
(1)胎体脏器细胞分离和培养液收集
取无菌脏器,反复冲洗后,剪成直径为1-2mm的组织块;依次经2型胶原酶和胰酶消化后,将上清液离心,取细胞沉淀放入培养瓶,使用含10%胎牛血清DMEM/F12培养基,5%CO2、37℃饱和湿度培养;去除非贴壁细胞,在贴壁细胞80%融合后更换无血清培养基培养48h,而后收集培养上清液,滤膜过滤得到富含外泌体的培养液;
(2)生理性流体预处理
利用离心或过滤方法去除生理性流体内的细胞成分,而后滤膜过滤得到富含外泌体的流体;
B、外泌体分离纯化
将(1)中的培养液或(2)中的流体依次经4℃,1000g离心10min;4℃,2000g离心20min;4℃,10000g离心30min;110000g离心90min后,弃上清,使用磷酸盐缓冲液重悬沉淀;再次110000g离心90min,弃上清,少量磷酸盐缓冲液重悬沉淀,0.45μm滤膜过滤,得到外泌体。
8.含有权利要求1~7任一项所述的胎体来源外泌体的皮肤调节产品,其特征在于,以所述外泌体为活性成分,还包括美容和皮肤病学可接受的赋形剂。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911179142.8A CN110840812A (zh) | 2019-11-27 | 2019-11-27 | 胎体来源的外泌体在皮肤调节产品中的用途 |
PCT/CN2020/130931 WO2021104214A1 (zh) | 2019-11-27 | 2020-11-23 | 胎体来源的外泌体在皮肤调节产品中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911179142.8A CN110840812A (zh) | 2019-11-27 | 2019-11-27 | 胎体来源的外泌体在皮肤调节产品中的用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110840812A true CN110840812A (zh) | 2020-02-28 |
Family
ID=69605022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911179142.8A Pending CN110840812A (zh) | 2019-11-27 | 2019-11-27 | 胎体来源的外泌体在皮肤调节产品中的用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN110840812A (zh) |
WO (1) | WO2021104214A1 (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111690600A (zh) * | 2020-04-16 | 2020-09-22 | 艾一生命科技(广东)有限公司 | 一种工程化人脐带间充质干细胞外泌体及透皮制剂与应用 |
WO2021104214A1 (zh) * | 2019-11-27 | 2021-06-03 | 沣潮医药科技(上海)有限公司 | 胎体来源的外泌体在皮肤调节产品中的用途 |
CN113307851A (zh) * | 2021-06-11 | 2021-08-27 | 北京戴域生物技术有限公司 | 一种改善皮肤生理特性的活性肽与间充质干细胞外泌体在药品或化妆品中的应用 |
CN113943700A (zh) * | 2021-10-21 | 2022-01-18 | 艾一生命科技(广东)有限公司 | 一种牛血清外泌体用于干细胞培养的方法 |
CN114045259A (zh) * | 2021-11-08 | 2022-02-15 | 山东第一医科大学(山东省医学科学院) | 一种抑制肿瘤干细胞的方法 |
CN114159374A (zh) * | 2021-12-10 | 2022-03-11 | 上海纳米技术及应用国家工程研究中心有限公司 | 用于皮肤抗衰老间充质干细胞外泌体组合物的制备方法及产品和应用 |
CN115537374A (zh) * | 2022-09-23 | 2022-12-30 | 杭州昱鼎生物科技有限公司 | 一种体液中提取外泌体的钠基蒙脱石(Na-MMT)吸附柱法 |
CN115778892A (zh) * | 2022-12-30 | 2023-03-14 | 广州赛莱拉生物基因工程有限公司 | 含有(动物)脐带提取物的头皮护理组合物及头皮护理产品 |
CN117024557A (zh) * | 2023-10-10 | 2023-11-10 | 天津外泌体科技有限公司 | 14-3-3蛋白theta异构体作为细胞外囊泡支架蛋白的应用和细胞外囊泡 |
CN117100673A (zh) * | 2023-10-23 | 2023-11-24 | 广州优特佳生物科技发展有限公司 | 一种调节毛囊周期的动物脐带提取物及其制备方法和应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170044999A (ko) * | 2015-10-16 | 2017-04-26 | (주)프로스테믹스 | 줄기세포 유래 엑소좀을 포함하는 상처 치료, 피부 개선 및 탈모 방지 또는 치료용 조성물 및 그 제조방법 |
CN107106613A (zh) * | 2014-11-07 | 2017-08-29 | 胞外体干细胞株式会社 | 用于成脂分化诱导、脂肪组织再生、皮肤美白或改善皱纹的包含干细胞来源外泌体的组合物 |
CN109464463A (zh) * | 2018-11-15 | 2019-03-15 | 陕西九州生物医药科技集团有限公司 | 间充质干细胞外泌体抗皮肤表皮细胞氧化的特性及其制剂的制备方法 |
CN110129265A (zh) * | 2019-05-20 | 2019-08-16 | 南京温博生物科技有限公司 | 一种脐带间充质干细胞外泌体、制备方法及在化妆品中的应用 |
CN110191714A (zh) * | 2017-01-11 | 2019-08-30 | 思特科技公司 | 制备用于毛发生长的组合物的方法,该组合物包含从引入了nanog的羊水中胎儿衍生间充质干细胞获得的外泌体 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105267240B (zh) * | 2014-12-16 | 2019-05-14 | 天津医科大学眼科医院 | 间充质干细胞来源的外泌体的用途 |
WO2017123022A1 (ko) * | 2016-01-12 | 2017-07-20 | 주식회사 강스템바이오텍 | 고함량의 성장인자를 함유한 줄기세포 유래 엑소좀 |
KR101885501B1 (ko) * | 2017-11-16 | 2018-08-06 | (주)프로스테믹스 | 녹용 줄기세포 배양액을 포함하는 피부 재생용 기능성 조성물 |
CN108143750B (zh) * | 2017-12-26 | 2020-09-15 | 湖北未来家园高科技农业股份有限公司 | 鹿胎盘外泌体的制备方法及应用 |
CN110037979B (zh) * | 2019-04-25 | 2020-08-18 | 广州优理氏生物科技有限公司 | 含羊间充质干细胞外泌体冻干粉及其制备方法 |
CN110184235B (zh) * | 2019-05-21 | 2021-03-02 | 葛楠 | 一种adsc外泌体及其制备方法与应用 |
CN110279648A (zh) * | 2019-06-24 | 2019-09-27 | 广州远想生物科技有限公司 | 一种含外泌体的美容制剂及用途 |
CN110464671A (zh) * | 2019-09-06 | 2019-11-19 | 天津珂芬迪斯生物医药科技有限公司 | 一种冻肽面霜及其制备方法 |
CN110840812A (zh) * | 2019-11-27 | 2020-02-28 | 沣潮医药科技(上海)有限公司 | 胎体来源的外泌体在皮肤调节产品中的用途 |
-
2019
- 2019-11-27 CN CN201911179142.8A patent/CN110840812A/zh active Pending
-
2020
- 2020-11-23 WO PCT/CN2020/130931 patent/WO2021104214A1/zh active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107106613A (zh) * | 2014-11-07 | 2017-08-29 | 胞外体干细胞株式会社 | 用于成脂分化诱导、脂肪组织再生、皮肤美白或改善皱纹的包含干细胞来源外泌体的组合物 |
KR20170044999A (ko) * | 2015-10-16 | 2017-04-26 | (주)프로스테믹스 | 줄기세포 유래 엑소좀을 포함하는 상처 치료, 피부 개선 및 탈모 방지 또는 치료용 조성물 및 그 제조방법 |
CN110191714A (zh) * | 2017-01-11 | 2019-08-30 | 思特科技公司 | 制备用于毛发生长的组合物的方法,该组合物包含从引入了nanog的羊水中胎儿衍生间充质干细胞获得的外泌体 |
CN109464463A (zh) * | 2018-11-15 | 2019-03-15 | 陕西九州生物医药科技集团有限公司 | 间充质干细胞外泌体抗皮肤表皮细胞氧化的特性及其制剂的制备方法 |
CN110129265A (zh) * | 2019-05-20 | 2019-08-16 | 南京温博生物科技有限公司 | 一种脐带间充质干细胞外泌体、制备方法及在化妆品中的应用 |
Non-Patent Citations (1)
Title |
---|
苏晓华: "牛胎肝间充质干细胞的分离培养基生物学特性研究", 《中国优秀硕士学位论文全文数据库》 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021104214A1 (zh) * | 2019-11-27 | 2021-06-03 | 沣潮医药科技(上海)有限公司 | 胎体来源的外泌体在皮肤调节产品中的用途 |
CN111690600A (zh) * | 2020-04-16 | 2020-09-22 | 艾一生命科技(广东)有限公司 | 一种工程化人脐带间充质干细胞外泌体及透皮制剂与应用 |
CN113307851A (zh) * | 2021-06-11 | 2021-08-27 | 北京戴域生物技术有限公司 | 一种改善皮肤生理特性的活性肽与间充质干细胞外泌体在药品或化妆品中的应用 |
CN113943700B (zh) * | 2021-10-21 | 2023-10-27 | 艾一生命科技(广东)有限公司 | 一种牛血清外泌体用于干细胞培养的方法 |
CN113943700A (zh) * | 2021-10-21 | 2022-01-18 | 艾一生命科技(广东)有限公司 | 一种牛血清外泌体用于干细胞培养的方法 |
CN114045259A (zh) * | 2021-11-08 | 2022-02-15 | 山东第一医科大学(山东省医学科学院) | 一种抑制肿瘤干细胞的方法 |
CN114045259B (zh) * | 2021-11-08 | 2024-04-05 | 山东第一医科大学(山东省医学科学院) | 一种抑制肿瘤干细胞的方法 |
CN114159374A (zh) * | 2021-12-10 | 2022-03-11 | 上海纳米技术及应用国家工程研究中心有限公司 | 用于皮肤抗衰老间充质干细胞外泌体组合物的制备方法及产品和应用 |
CN115537374A (zh) * | 2022-09-23 | 2022-12-30 | 杭州昱鼎生物科技有限公司 | 一种体液中提取外泌体的钠基蒙脱石(Na-MMT)吸附柱法 |
CN115778892A (zh) * | 2022-12-30 | 2023-03-14 | 广州赛莱拉生物基因工程有限公司 | 含有(动物)脐带提取物的头皮护理组合物及头皮护理产品 |
CN117024557A (zh) * | 2023-10-10 | 2023-11-10 | 天津外泌体科技有限公司 | 14-3-3蛋白theta异构体作为细胞外囊泡支架蛋白的应用和细胞外囊泡 |
CN117024557B (zh) * | 2023-10-10 | 2024-01-30 | 天津外泌体科技有限公司 | 14-3-3蛋白theta异构体作为细胞外囊泡支架蛋白的应用和细胞外囊泡 |
CN117100673A (zh) * | 2023-10-23 | 2023-11-24 | 广州优特佳生物科技发展有限公司 | 一种调节毛囊周期的动物脐带提取物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2021104214A1 (zh) | 2021-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021104214A1 (zh) | 胎体来源的外泌体在皮肤调节产品中的用途 | |
CN111053716B (zh) | 一种茯茶提取物在制备皮肤调节产品中的用途 | |
US10688142B2 (en) | Methods of treatment using a lipid extract of Passiflora seeds concentrated in its unsaponifiable fraction | |
US8709511B2 (en) | External preparation composition for skin comprising ginseng flower or ginseng seed extracts | |
CN102481245B (zh) | 包含五味子的肽提取物的治疗痤疮用化妆品组合物 | |
US9282759B2 (en) | Composition including an unsaponifiable fraction | |
KR102239121B1 (ko) | 당 비함유 파인애플 추출물과 그 제조 방법 및 그 용도 | |
ES2523853T3 (es) | Uso de un extracto de Wolfberry para mantener y/o restaurar la tonicidad y/o la firmeza de la piel | |
KR20190005369A (ko) | 씨-피코시아닌을 유효성분으로 함유하는 피부 주름의 예방 또는 개선용 조성물 | |
KR101059471B1 (ko) | 피부 노화 방지용 화장료 조성물 | |
US10092495B2 (en) | Use of a composition comprising avocado perseose in the protection of epidermal stem cells | |
KR101906604B1 (ko) | 동부 종자 추출물 및 이를 함유한 조성물 | |
KR20180047952A (ko) | 녹용 줄기세포 배양액을 포함하는 기능성 조성물 | |
KR20180048431A (ko) | 녹용 줄기세포 배양액을 포함하는 피부 재생용 기능성 조성물 | |
JP2018534337A (ja) | 天然抽出物を含有する組成物、ならびに皮膚および毛髪に対するその使用 | |
KR20130088997A (ko) | 생캐비어 추출물 및 발효추출물을 이용한 육모, 발모, 탈모방지 및 두피 개선용 화장료 조성물 | |
JP2022125278A (ja) | プロフィラグリンmRNA発現促進剤、セリンパルミトイルトランスフェラーゼmRNA発現促進剤、ヒアルロン酸合成酵素3mRNA発現促進剤及び抗老化剤 | |
KR101124441B1 (ko) | 마그네슘 아스코르빌 포스페이트(map) 및 메틸설포닐메탄(msm) 혼합물을 유효성분으로 함유하는 탈모 방지 및 발모 개선용 조성물 | |
CA2885679A1 (en) | Oral composition for reinforcing skin tolerance following topical administration of a retinoid compound | |
JP6827691B2 (ja) | 化粧料 | |
CN110403890A (zh) | 包括鲟鱼卵提取物和鲟鱼羊水提取物的用于皮肤美容的组合物 | |
KR20140081982A (ko) | 만가닥버섯 자실체 추출물 또는 만가닥버섯 균사체 추출물을 함유하는 피부 외용제 조성물 | |
KR20070109886A (ko) | 파파야를 기재로 한 외용 화장품 또는 약품 | |
JP2021138665A (ja) | メラニン生成抑制剤、表皮ターンオーバー促進剤、及び抗酸化遺伝子発現促進剤 | |
KR20200145383A (ko) | 정제어유 유래 오메가-7 및 홍삼을 포함하는 피부 상태 개선용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200228 |